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The diff erential diagnosis of neurodegenerative brain diseases may be diffi  cult on clinical 
grounds only, especially at an early disease stage. Neurodegenerative brain diseases such as 
Parkinson’s Disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), 
corticobasal degeneration (CBD), dementia with Lewy Bodies (DLB), Alzheimer’s Disease (AD) and 
frontotemporal dementia (FTD) have overlapping features at presentation, while the typical clinical 
syndrome may become clear only at later disease stages. For this reason, there is increasing interest 
to use neuroimaging techniques in the hope to discover abnormal patterns of brain structure, 
energy consumption or network activity which are characteristic of such diseases. It is important 
to determine the relationship between biochemical brain activities and disease processes. Positron 
emission tomography (PET) tracer methods assess specifi c biochemical activities of the human 
brain and can be used to obtain insight in the pathophysiology of brain diseases. 
In this thesis, the results of increasing possibilities of investigating resting brain activity 
in neurodegenerative brain diseases using [18F]-fl uorodeoxyglucose (FDG)-PET and magnetic 
resonance techniques imaging will be discussed.
The main objectives were to investigate diff erences in glucose metabolism and other image 
modalities in various neurodegenerative brain diseases using diff erent analysis techniques. A 
general introduction and the results are presented in the following chapters.
OUTLINE OF THE THESIS
In chapter 2 an introduction on Parkinson’s Disease and diff erent molecular imaging techniques is 
given including the relevance for clinical practice. 
In chapter 3 specifi c regional diff erences of brain metabolism applying [18F]-fl uoro- deoxyglucose 
positron emission tomography (FDG-PET), were identifi ed in seven diff erent neurodegenerative 
brain diseases when they were compared to a healthy control group using univariate methods. In 
chapter 4 the usefulness of FDG-PET in investigating diff erent neurodegenerative brain diseases 
and applying more advanced multivariate analysis methods like the scaled subprofi le model (SSM), 
principal component analysis (PCA) is reviewed.
In chapter 5 en 6 this SSM/PCA analysis technique is further investigated in our own population 
with parkinsonian syndromes in chapter 5 and in Alzheimer’s Disease in chapter 6, suggesting that 
this method can assist in early diff erential diagnosis of neurodegenerative brain diseases. In chapter 
7 the national database project GLucose IMaging in ParkinsonismS (GLIMPS) is introduced. The 
background, design and goal of the project will be outlined.
In chapter 8 a PD-related metabolic and perfusion covariance pattern is identifi ed using perfusion-
MRI and FDG-PET imaging and (dis)similarities in the disease-related pattern between perfusion 
and metabolism in PD patients is assessed. 
Chapter 9 provides an overview, discussion and future perspectives of the disease-specifi c brain 
patterns presented in this thesis.
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MOLECULAR IMAGING IN PARKINSON’S DISEASE
L.K. TEUNE & K.L. LEENDERS
Department of Neurology, University Medical Center Groningen, the Netherlands
Neuromethods (2012): Molecular Imaging in the Neurosciences,




Parkinson’s disease (PD) is manifested clinically by bradykinesia, muscular rigidity and sometimes 
rest tremor. The pathological hallmark of PD is the degeneration of dopaminergic cells within the 
substantia nigra-pars compacta (SNc) and the subsequent dopamine depletion of the striatum. 
Besides disturbances in motor performance, other symptoms like REM sleep behavior disorder, 
autonomic dysfunction, depression and cognitive defi cits can play a role in PD. It can be diffi  cult 
to distinguish PD from other neurodegenerative brain diseases, but early diagnosis is important 
because prognosis and treatment options diff er. Structural imaging is in general not helpful at early 
disease stages. However, nuclear imaging methods can display striatal dopaminergic activity in PD, 
but also visualize brain perfusion and glucose metabolism to show disease related changes in local 
brain function or identify cholinergic defi cits associated with cognitive dysfunction. Presynaptic 
dopaminergic imaging either with PET or SPECT is the gold standard to diff erentiate between 
patients with parkinsonian features associated with and without a presynaptic dopaminergic 
defi cit. In order to diff erentiate between PD and other neurodegenerative brain diseases, specifi c 
disease related metabolic patterns identifi ed with FDG-PET imaging could be of great assistance in 
the individual clinical diagnosis.
1.1 INTRODUCTION
Parkinson’s disease (PD) is the second most common neurodegenerative brain disease after 
Alzheimer’s disease. The prevalence of PD in industrialized countries is generally estimated at 
0.3% of the entire population and about 1% in people over 60 years of age. Reported standardized 
incidence rates of PD are 8-18 per 100000 person-years (de Lau and Breteler. 2006). PD is manifested 
clinically by bradykinesia, muscular rigidity and sometimes rest tremor. Supportive features of the 
diagnosis are a unilateral onset of motor symptoms, progressive disorder and a good and consistent 
levodopa response (Litvan, et al. 2003).
The basal ganglia, which consist of the striatum (putamen, caudate nucleus) together with 
globus pallidus pars interna and externa (GPi, GPe), substantia nigra pars reticulata and compacta 
(SNr, SNc) and subthalamic nucleus (STN) play a role in motor control, but they are also involved 
in various emotional and cognitive functions (Alexander, et al. 1986). The pathological hallmark of 
PD is the degeneration of dopaminergic neurons within the SNc and the subsequent dopamine 
depletion of the striatum, especially putamen. Via diff erent types of dopamine receptors in the 
two populations of striatal output neurons, dopamine has an opposing eff ect on the basal ganglia 
output nuclei (GPi and SNr) and thus on the thalamic targets of these nuclei. Via the dopamine 
D1 receptor the activity of the direct pathway is facilitated. Activation of the direct pathway which 
projects directly to the GPi and SNr disinhibits the thalamus and thereby increases thalamocortical 
activity. 
The indirect pathway passes fi rst in a GABAergic way to the GPe and STN, and fi nally in an excitatory 
glutamatergic projection from the STN to the GPi, thereby inhibiting thalamocortical neurons. 
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The dopamine D2 receptor reduces transmission in the indirect pathway (DeLong and Wichmann. 
2009, Groenewegen and van Dongen Y.C. 2008) (Figure 1). So although their synaptic actions are 
diff erent, the dopaminergic inputs to the two pathways lead to the same eff ect, namely reducing 
inhibition of the thalamocortical neurons and thus facilitating movements initiated in the cortex. 
As mentioned before, in PD dopamine is depleted, which leads to reduced inhibition of the 
indirect pathway and reduced excitation of the direct pathway, with the net result of an excessive 
activation of the BG output nuclei and inhibition of thalamocortical and brainstem motor systems, 
leading to parkinsonian motor features (Bartels and Leenders. 2009, DeLong and Wichmann. 2007, 
Groenewegen. 2003). 
Figure 1:  Direct and indirect striatal output pathways and the infl uence of dopamine on these routes, repre-
sented in a semi-sagittal scheme of the cerebral cortex and the basal ganglia. The direct pathway runs from the 
striatum to the internal segment of the globus pallidus and the substantia nigra pars reticulata. This pathway 
contains the peptides substance P (SP) and dynorphin (DYN) as well as the dopamine D1 receptor. The fi rst link 
in the indirect striatal output pathway consists of the projections from the striatum to the external segment of 
the globus pallidus. These striatal neurons express the peptide enkephalin (ENK) and contain the dopamine D2 
receptor. The subsequent steps in the indirect route are the pallido-subthalamic and the subthalamo-pallidal 
projections. Dopamine has opposite eff ects on the two striatal output routes, stimulating the direct pathway 
and inhibiting the indirect pathway. Abbreviations: Acb, nucleus accumbens; Caud, caudate nucleus; GPe, ex-
ternal segment of the globus pallidus; GPi, internal segment of the globus pallidus; MC, primary motor cortex; 
MD, mediodorsal thalamic nucleus; O, occipital cortex; P, parietal cortex, PFC, prefrontal cortex; Put, putamen; 
sc, central sulcus; SNC, substantia nigra pars compacta; SNR, substantia nigra pars reticulata; STN, subthalamic 
nucleus; T, temporal cortex; VA, ventral anterior thalamic nucleus; VL, ventral lateral thalamic nucleus.
(Reproduced with permission: Wolters, van Laar, Berendse (eds.) Parkinsonism and Related Disorders. Amster-
dam, VU University Press, 2008)
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Especially at early disease stages in PD, levodopa administration is highly eff ective for improving 
motor symptoms. Long-term treatment is accompanied by fl uctuations in motor performance and 
dyskinesias. As PD progresses, patients develop features which are diffi  cult to treat, such as freezing 
episodes, autonomic dysfunction (orthostatic hypotension), depression and dementia (Horstink, 
et al. 2006). Deep brain stimulation (DBS) of the STN can be a highly eff ective and increasingly 
used treatment for selected patients in advanced disease stages. Reduction of motor fl uctuations 
and disappearance of levodopa induced dyskinesias after dosage reduction of antiparkinsonian 
medication are the main features of this intervention (Asanuma, et al. 2006, Limousin, et al. 1998).
Although the clinical progression and treatment response of PD is diff erent from other parkinsonisms 
such as multiple system atrophy (MSA) and dementia with Lewy Bodies (DLB), they share the 
pathological feature of disturbed α-synuclein and are designated as α-synucleinopathies (Gilman, et 
al. 2008, McKeith. 2006). α-Synuclein is a structural protein localized primarily to synaptic terminals. 
In PD and DLB α-synuclein is a key component of the pathological hallmark Lewy Body and in 
MSA there are α-synuclein containing glial cytoplasmic inclusions (Galpern and Lang 2006). Other 
neurodegenerative brain diseases with parkinsonism like progressive supranuclear palsy (PSP) and 
corticobasal degeneration (CBD) show disturbances in tau protein handling and are designated as 
tauopathies (Galpern and Lang 2006, Litvan, et al. 1996, Mahapatra, et al. 2004). It can be diffi  cult 
to distinguish PD from other neurodegenerative brain diseases, especially at early disease stages 
and on clinical grounds only.  Structural imaging is in general not helpful at early disease stages. 
However, nuclear imaging methods can display striatal dopaminergic activity in PD, but also 
visualize brain perfusion and glucose metabolism to show disease related changes in local brain 
function or identify cholinergic defi cits associated with cognitive dysfunction (Hilker, et al. 2005, 
Leenders, et al. 1984b). These techniques gain further insight in pathological mechanisms in PD 
and assist in the diff erential diagnosis of neurodegenerative brain diseases. In the next paragraphs, 
nuclear imaging methods which display diff erent aspects of pathological mechanisms in PD will be 
further discussed. 
2.2 STRIATAL DOPAMINERGIC IMAGING
Radiotracer neuroimaging techniques using positron emission tomography (PET) or single 
photon emission computed tomography (SPECT) can be helpful in visualizing and measuring 
striatal dopaminergic activity in patients with parkinsonism (Innis, et al. 1993, Leenders, et al. 
1990). Dopamine synthesis takes place within the striatal nerve terminals of dopaminergic 
neurons (Figure 2). Radioactive tracers can bind to the dopamine transporter (DAT), the vesicular 
monoamine transporter 2 (VMAT2) and the enzyme aromatic-amino-acid decarboxylase (AADC). 
The dopaminergic system can be measured using diff erent tracers (Piccini and Whone 2004). 
15
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2.2.1 Presynaptic dopaminergic imaging
The most widely used PET tracer to study the presynaptic dopaminergic system in PD is 6- [18F] 
fl uoro-L-3, 4-dihydroxyphenylalanine (FDOPA). It estimates the rate of decarboxylation of FDOPA 
to [18F]-fl uorodopamine by AADC, a function of striatal levodopa decarboxylase activity (Figure 2). 
[18F] FDOPA striatal uptake rate is correlated to cellular density of substantia nigra dopaminergic 
neurons and to striatal dopamine concentrations (Garnett, et al. 1983, Leenders, et al. 1986). In early 
PD patients, FDOPA uptake is diminished primarily in the posterior putamen and relatively preserved 
in the anterior putamen and caudate (Leenders, et al. 1990). In healthy controls the ratio of posterior 
putamen to caudate nucleus is about 1, whereas in early PD this ratio is around 0.6. In MSA patients, 
this gradient is not present and FDOPA uptake is reduced in both caudate and putamen (Otsuka, 
et al. 1996, Piccini and Whone. 2004). Nonetheless, subsequent studies have shown that caudate/
putamen diff erences are not suffi  ciently reliable to categorize individual cases. Another method 
to distinguish healthy controls from PD patients is to look for asymmetrical uptake between the 
left and right putamen. In healthy controls there is no asymmetry and in early PD the putamen 
contralateral to the most aff ected diseased body side is more decreased (Leenders, et al. 1990) 
Using SPECT and PET, the uptake of tracers with a high affi  nity for the dopamine transporter 
(DAT) can be measured (Booij, et al. 1997, Rinne, et al. 1995, Rinne, et al. 1999, Volkow, et al. 1995). 
Figure 2: Schematic representation of dopa-
mine synthesis within dopaminergic neurons, 
including sites of action of dopaminergic trac-
ers (a,b,c,d). Dopamine (DA) synthesis takes 
place within nerve the striatal nerve terminals 
of dopaminergic neurons. Within the cytoplasm 
of dopaminergic terminals, tyrosine is fi rst con-
verted to L-3,4,-dihydroxyphenylalanine (L-do-
pa) by the enzyme tyrosine hydroxylase (TH). L-
dopa is then decarboxylated by aromatic amino 
acid decarboxylase (AADC) to DA. The synthe-
sized DA enters the presynaptic vesicles via the 
vesicular monoamine transporter type 2 (VMAT 
2). Following depolarization of nerve terminals, 
the stored DA is released into the synaptic cleft 
and interacts with pre- and postsynaptic DA 
receptors. a) The PET tracer [18F] FDOPA binds 
to AADC and estimates the rate of decarbox-
ylation of FDOPA to [18F]-fl uorodopamine by 
AADC which represents a function of striatal le-
vodopa decarboxylase activity b) the PET tracer 
[11C]-DTBZ binds to VMAT2 and blocks the 
uptake of monoamines into the vesicles which 
represents the integrity of striatal monoaminergic nerve terminal density. c) The SPECT tracers [123 I]FP-CIT) and 
[123 I]β-CIT bind to the DA transporter which represents a marker of the integrity of presynaptic nigrostriatal 
dopamine terminals. d) The PET tracer [11C]-raclopride and the SPECT tracer [123I] iodobenzamide IBZM bind to 
the postsynaptic dopamine D2 receptor which allows the visualization of striatal dopamine D2 receptor binding.
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However, in clinical practice mostly SPECT is used, because this is more widely available. DATs are 
located on dopaminergic nerve endings and facilitate the release and reabsorption of dopamine in 
the presynaptic terminals and are modulated by the concentration of endogenous dopamine (Innis, 
et al. 1993). Striatal DAT binding represents a marker of the integrity of presynaptic nigrostriatal 
dopamine terminals and can be assessed with a variety of radio labeled cocaine derivatives, 
including [123 I]FP-CIT) and [123 I]β-CIT-SPECT (Figure 2). Several studies have demonstrated that 
striatal β-CIT and FP-CIT uptake is reduced in patients with PD compared to controls (Booij, et al. 
1997, Innis, et al. 1993, Rinne, et al. 1995, Tissingh, et al. 1998). Eshuis et al. demonstrated that both 
FP-CIT SPECT and F-DOPA-PET are equally able to distinguish patients with parkinsonian syndromes 
from healthy controls (Eshuis, et al. 2009) 
Since the mid-1990s [11C]-dihydrotetrabenazine (DTBZ)-PET has been used in humans to monitor 
the integrity of striatal monoaminergic nerve terminal density. However, nowadays it is only used 
in a few research centers in the world. Tetrabenazine binds to VMAT2 (a protein responsible for the 
uptake of monoamines into the synaptic vesicles) and blocks the uptake of monoamines into the 
vesicles (Figure 2) (Lee, et al. 2000). DTBZ has an advantage over FDOPA and DAT ligands in the 
sense that it has limited peripheral metabolism and is not subject to pharmacological regulation. 
However, the main disadvantage is the non-specifi city for dopamine (Au, et al. 2005). 
Presynaptic dopaminergic imaging can also be used to distinguish between PD patients and 
vascular parkinsonism or essential tremor, (Figure 3) (Gerschlager, et al. 2002, Marshall, et al. 2006) 
but not between PD and other parkinsonisms such as MSA and PSP (Piccini and Whone. 2004) 
Figure 3: Example of individual patients with and without a presynaptic dopaminergic defi cit using two diff er-
ent tracers. Above examples of a FP-CIT-SPECT scan and below examples of an FDOPA-PET scan. a) individual 
without a presynaptic dopaminergic defi cit (essential tremor) and b) individual with a presynaptic dopaminer-
gic defi cit (patient with Parkinson’s Disease).
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Functional imaging of the presynaptic nigrostriatal dopaminergic system has been used to assess 
the rate of disease progression in PD (Brooks, et al. 2003, Hilker, et al. 2005, Pavese, et al. 2009, Pirker, 
et al. 2003, Rinne, et al. 1995, Volkow, et al. 1998). Using FDOPA-PET in PD, a more rapid decline in 
the putamen was observed than in the caudate nucleus, giving an overall annual rate of decline of 
5.3% in the total striatum of FDOPA uptake (Morrish, et al. 1998). 
There are also a number of longitudinal SPECT studies which report annual rates of progression 
between 5-8% of baseline in the striatum. However, DAT-SPECT does not have the anatomical 
resolution to detect subregional diff erences in rate of progression (Au, et al. 2005, Pirker, et al. 2003).
Now that there is a marker of disease progression, it is also possible to study treatment interventions 
that may have an eff ect on disease progression. The CALM-PD study compared the early use of 
pramipexole with levodopa, using β-CIT-SPECT as an imaging modality, (Parkinson Study Group 
2000) the REAL-PET study compared ropinirole vs levodopa in de novo PD patients and used FDOPA-
PET as a marker to assess disease progression (Whone, et al. 2003) and in the ELLDOPA trial the eff ects 
of levodopa on clinical progression were studied using β-CIT-SPECT as an imaging modality (Fahn 
2005). Furthermore, a few studies have been conducted to assess the eff ects of human embryonic 
dopaminergic tissue transplantation and they used FDOPA-PET to monitor imaging changes (Ma, et 
al. 2010b). Overall the results of these studies show no clear eff ect of dopamine agonist treatment 
on disease progression as indicated by striatal dopaminergic features. The radiotracer methods 
applied in these studies are adequate, but simply an eff ective infl uence of the drug treatment on 
neuronal degeneration has been absent. On the other hand, if indeed a change of local striatal 
dopaminergic activity takes place as is the case after implantation of embryonic dopaminergic cells, 
then the applied radiotracer methods do indeed refl ect these changes.
Also it has been investigated whether DBS treatment of parkinsonian patients would halt or slow 
further progression of the disease since STN-DBS is expected to reduce the glutamatergic fi ring of 
the STN. One study investigated this but did not see an alteration of striatal FDOPA uptake in PD 
patients after implantation (Hilker, et al. 2005).
2.2.2 Postsynaptic dopaminergic imaging
One diff erence in striatal pathology between PD and other diseases like MSA and PSP can be 
evaluated by investigation of the postsynaptic dopamine D2 receptor. Examples of receptor 
binding ligands include [11C]-raclopride for PET imaging and [123I] iodobenzamide (IBZM) for 
SPECT imaging (Figure 2) (Farde, et al. 1985, Kung, et al. 1990). Several studies have shown that 
D2 receptors may be up-regulated in early untreated PD patients, but in later disease stages there 
is a reduction in striatal D2 receptor binding (Antonini, et al. 1997, Brooks, et al. 1992). Neurons 
containing dopamine 2 receptors are especially aff ected in patients with MSA and PSP (Brooks, et al. 
1992, Schwarz, et al. 1993, Schwarz, et al. 1994). The diff erential diagnosis between PD and MSA or 
PSP using postsynaptic dopaminergic imaging is diffi  cult because D2 receptor binding also declines 
in PD at later disease stages. Therefore [11C]-raclopride-PET and IBZM-SPECT are not recommended 
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to use for this indication. In more recent studies [11C]-raclopride is used to study medication eff ects 
in PD (Pavese, et al. 2006) 
2.3 REGIONAL BLOOD FLOW AND GLUCOSE METABOLISM 
In addition to changes in striatal dopaminergic activity, nuclear imaging techniques can be used to 
visualize disease-related changes in local brain function using tracers for regional brain perfusion 
and glucose metabolism. Sokoloff  et al. were the fi rst to report that under physiological steady 
state conditions, cerebral blood fl ow (CBF) is coupled to the level of cerebral oxygen (CMRO2) and 
glucose consumption (CMRglc) (Sokoloff , et al. 1977). Furthermore, they established that functional 
activity in specifi c components of the central nervous system, is closely coupled to the local rate of 
energy metabolism. Stimulation of functional activity increases the local rate of glucose utilization 
and reduced functional activity lowers it (Sokoloff . 1977). There are diff erent PET and SPECT tracers 
to visualize blood fl ow, oxygen and glucose consumption which will be discussed. 
2.3.1 Brain perfusion
The distribution for regional cerebral blood fl ow (rCBF) and regional oxygen metabolism (rCMRO2) 
is related to neuronal and synaptic functional activity. PET provides the opportunity to make 
regional measurements of rCBF and rCMRO2. Frackowiak et al. applied the PET tracers which 
were labeled with 15O to measure regional blood fl ow and oxygen metabolism (Frackowiak, et al. 
1980) Since then, this tracer has been used to study brain perfusion in diff erent clinical conditions. 
Leenders et al. measured rCBF and rCMRO2 in PD patients. They showed an increase of regional 
blood fl ow and oxygen metabolism in the basal ganglia of the aff ected hemisphere in PD patients 
with predominantly unilateral disease (Leenders, et al. 1984a). Furthermore, they studied the eff ect 
of levodopa administration on cerebral blood fl ow and they found a diff use increase in rCBF after 
levodopa administration without stimulation of regional oxygen utilization. The eff ect of levodopa 
on rCBF did not correlate with the degree of clinical improvement and they suggest that the rise in 
rCBF is caused by vasodilatation due to a direct eff ect of levodopa on blood vessels (Leenders, et al. 
1985). In the 80’s, a SPECT tracer, 99Tcm-hexamethylpropyleneamine oxime (99Tcm-HM-PAO), was 
also developed to detect cerebral blood fl ow with SPECT-imaging (Holmes, et al. 1985, Leonard, 
et al. 1986). Nowadays, measurements of rCBF with PET or SPECT are not used in clinical practice, 
because it is a demanding and time-consuming procedure. For research purposes, the upcoming of 
functional magnetical resonance imaging (fMRI) in the 1990s, which measures the hemodynamic 
response function has made it easier to study changes in cerebral blood fl ow for example in task 
specifi c activation studies. Changes in Blood Oxygen Level Dependence (BOLD), which is the MRI 
contrast of blood deoxyhemoglobin, are well correlated to changes in blood fl ow (Kwong, et al. 
1992). Since blood fl ow and brain metabolism are closely coupled, brain metabolism is measured 
with FDG-PET imaging in clinical practice to study regional diff erences in metabolism between 
diseases (see below). 
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2.3.2 Brain glucose metabolism
The PET tracer [18F]-fl uorodeoxyglucose (FDG) allows the measurement of cerebral metabolic 
rate of glucose (CMRglc). FDG is a glucose analogue with physiological aspects almost identical to 
glucose. It is transported from the blood to the brain by a carrier-mediated diff usion mechanism. 
Glucose is then phosphorylized to glucose-6-PO4, and FDG to FDG-6-PO4, katalyzed by hexokinase. 
While glucose phosphate is metabolized further to carbon dioxide and water, FDG phosphate is 
not a substrate for any enzyme known to be present in brain tissue and is trapped for some longer 
time and therefore a useful imaging marker.  Reivich et al. were the fi rst to study  FDG-PET in man 
(Reivich, et al. 1979) 
Since then, FDG-PET imaging has been used to identify characteristic disease-related patterns of 
regional glucose metabolism in patients with parkinsonism (Eckert, et al. 2005, Juh, et al. 2004, 
Teune, et al. 2010) (Figure 4).
Figure 4: SPM (t) maps of decreased metabolic activity were overlaid on a T1 MR template thresholded at P< 
0.001 with cluster cutoff  of 20 voxels. Patient groups are indicated on the vertical axis and on the horizontal axis, 
seven transversal slices through the brain are shown. PD = Parkinson’s Disease: Decreased metabolic activity in 
the contralateral to the most aff ected body side parieto-occipital and frontal regions; MSA = Multiple system at-
rophy: Decreased metabolic activity in bilateral putamen and cerebellum; PSP = progressive supranuclear palsy: 
decreased metabolic activity in the prefrontal cortex, caudate nucleus, thalamus and mesencephalon; CBD = 
corticobasal degeneration:  Decreased metabolic activity in the contralateral to the most aff ected body side 
cortical regions; DLB = dementia with Lewy Bodies: Decreased metabolic activity in the occipital and parieto-




A characteristic metabolic pattern is identifi ed in PD patients using principal component analysis 
showing regionally relatively increased metabolism in the globus pallidus and putamen, thalamus, 
pons and cerebellum and relatively decreased metabolism in the lateral frontal, premotor and 
parietal association areas. Ma et al. reproduced this Parkinson disease-related covariance pattern 
(PDRP) using H215O PET scanning (Eidelberg, et al. 1994, Ma, et al. 2007a). Increased striatal FDG 
uptake in PD patients is explained by loss of inhibitory nigrostriatal dopaminergic input, leading to 
functional overactivation of the putamen (Eggers, et al. 2009). Network expression in Parkinson’s 
disease also increases linearly with disease progression (Huang, et al. 2007c) 
FDG-PET studies have also been performed to study eff ects of treatment and their relations with 
neural network pathophysiology. A study using an automated approach for quantifying network 
activity in single scans, found that both STN DBS and levodopa therapy were associated with 
downward modulation of the PDRP. Furthermore, brain regions like the premotor cortex and post 
parietal areas which are reduced in untreated PD, rise after treatment with levodopa or STN DBS, 
presumably by increasing excitatory aff erent activity from the thalamus (Asanuma, et al. 2006).
Furthermore, STN DBS was found to activate glucose metabolism in the frontal limbic and associative 
territory (Hilker, et al. 2004). Hilker et al. investigated the metabolic eff ects of high frequency DBS of 
the STN and they conclude that STN-DBS excites the subthalamic area and the directly connected 
pallidum via an increased neuronal output originating from the stimulation site (Hilker, et al. 2008). 
Recently, newly developed high resolution PET scanners with a FWHM of 2.5 mm permits the 
determination of regional FDG uptake in small subcortical nuclei, showing a signifi cantly higher 
CMRGlc in PD patients compared to controls bilaterally in the basal ganglia output nuclei (pallidum 
and substantia nigra) and unilateral in the caudate and putamen (Eggers, et al. 2009).
Several studies have used FDG-PET imaging to diff erentiate PD from other diseases (Eckert and 
Eidelberg. 2004, Klein, et al. 2010, Klein, et al. 2005, Otsuka, et al. 1997, Yong, et al. 2007). Eckert et 
al. demonstrated disease-related metabolic patterns for MSA and PSP. The MSA-related pattern was 
characterized by decreased metabolism in putamen and cerebellum and the PSP-related pattern 
consisted of mediofrontal hypometabolism and hypometabolism of the brainstem (Eckert, et al. 
2008). Using an automated image-based classifi cation procedure, individual patients could be 
diff erentiated in PD, MSA and PSP categories with high specifi city (Tang, et al. 2010b) In contrast 
to the cognitive problems that are related to PD itself, in PD patients with dementia (PDD), and 
DLB patients compared to controls, decreased metabolism was found in parietal, frontal, anterior 
cingulate and in occipital areas. The metabolic defi cits were more extensive in DLB than in PDD. In 
comparison with PD patients, those with DLB and PDD showed greater metabolic defi cits in parietal 
and frontal regions (Yong, et al. 2007). 
For clinical practice disease specifi c patterns as found in PD and other neurodegenerative 
diseases with parkinsonism can be a valuable aid in the diff erential diagnosis. One should realize 
that the patterns show relative metabolic increases and decreases and not absolute values of 
glucose consumption. In PD however, mostly cortical decreases are not clear on visual inspection 
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and sometimes an accentuated striatum is shown. In contrast, metabolic decreases in other 
parkinsonisms can be detected with visual inspection (Figure 5).
Figure 5: Individual FDG-PET scans of 4 patients. a) Patient with Parkinson’s Disease: normal FDG uptake in the 
cortical regions, normal or slightly elevated uptake in the putamen; b) patient with multiple system atrophy: de-
creased FDG uptake in the cerebellum and striatum; c)  patient with progressive supranuclear palsy: decreased 
FDG uptake in the mediofrontal regions; d) patient with corticobasal degeneration: contralateral to the most 




Many patients with PD develop mental dysfunction ranging from subtle cognitive defi cits to 
severe dementia (PDD). Cholinergic defi cits probably play an important role in the pathogenesis 
of PD-associated dementia. N-[11C]-methyl-4-piperidyl acetate (MP4a) is an established radiotracer 
for quantifi cation of cerebral acetylcholinesterase activity.  It has been used to assess defi ciency 
of cholinergic innervation in AD, PSP but also in PD, PDD and DLB, and for the assessment of the 
pharmacological eff ect of cholinesterase inhibitors. Hilker et al. (Hilker, et al. 2005)studied patients 
with PD and PDD with combined PET [11C]-MP4A and [18F]-fl uorodopa (FDOPA)-PET for evaluation 
of cholinergic and dopaminergic transmitter changes. They conclude that while non-demented 
PD patients had a moderate cholinergic dysfunction, patients with PDD presented with a severe 
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cholinergic defi cit in various cortical regions. In a recent study of Klein et al. (Klein, et al. 2010), PDD 
and DLB patients were compared with PD patients without dementia and they found in PDD as well 
as DLB a marked MP4A and FDG reduction in cortical areas compared to PD. Both studies did not 
fi nd a signifi cant diff erence in cortical and striatal FDOPA uptake between PD and PDD/DLB patients 
suggesting that cholinergic dysfunction seems to be crucial for the development of dementia in 
addition to the dopamine system related motor symptoms. Clinically, these data support the notion 
that cognitive function deteriorates in some predisposed patients with PD after administration 
of anticholinergic drugs (Ehrt, et al. 2010). Furthermore, they support the eff ect of cholinesterase 
inhibitors in PDD on cognition as has been shown in a placebo controlled trial with rivastigmine 
(Emre, et al. 2007). Recently, an 18F-labeled derivative of 11CMP4A, [18F] fl uoroethylpiperidin-
4ylmethyl acetate ([18F] FEP-4MA) showed desirable properties for quantifi cation of cerebral AChE 
activity by PET. This could potentially make measurement of AChE more widely applicable because 
of the longer half life of 18F than 11C, making it possible to transport the tracer from a center 
equipped with a cyclotron to other PET centers (Kikuchi, et al. 2010). 
2.4.2 Neuroinfl ammation
 [11C]-PK11195 PET, a peripheral benzodiazepine receptor has been used for in vivo brain imaging 
of microglia activation in PD patients. An increased number of activated microglia has been found 
in the SN of PD brains and animal studies have suggested the relevance of microglia activation to 
cell death (Teismann, et al. 2003). Ouchi et al. studied microglial activation using  [11C]-PK11195 PET 
in PD patients and found increases in midbrain binding potential of PK11195 correlated inversely 
with a dopamine transporter marker in putamen and correlated positively with clinical motor scores 
(Ouchi, et al. 2005). In contrast, Gerhard et al. found increased PK binding in the pons, basal ganglia 
and frontal, temporal cortical regions in PD patients which did not correlate with clinical severity of 
putamen 18FDOPA uptake. They suggested that microglia are activated early in the disease course 
and levels then remain relatively static (Gerhard, et al. 2006). This increased infl ammation in basal 
ganglia and midbrain could not be reproduced by Bartels et al. (Bartels, et al. 2010). They found 
variable results with diff erent methods of analysis. Therefore they conclude that tracers with higher 
levels of specifi c binding in brain and better capacity to quantify peripheral benzodiazepine receptor 
expression should be developed, because radiotracer studies that can monitor neuroinfl ammatory 
processes within the brain will be of great value for the translation of potentially eff ective treatments.
2.4.3 Adenosine system
Adenosine is an endogenous inhibitory neurotransmitter and modulates functions within the 
central nervous system. Adenosine A1 receptors (A1Rs) are widely distributed throughout the brain 
but adenosine A2A receptors (A2ARs) are highly concentrated within the basal ganglia (Fredholm 
and Svenningsson. 2003, Jarvis, et al. 1989). Adenosine A2A receptors have a selective localization 
to the basal ganglia and specifi cally to the GABAergic neurons of the indirect pathway which also 
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expresses the D2 dopamine receptor. This off ers an opportunity to modulate the output from 
the striatum and A2a antagonists could infl uence motor function in experimental models in PD 
suggesting that it might be eff ective as a symptomatic treatment in humans without provoking 
marked dyskinesias (Jenner, et al. 2009). Mishina et al. investigated the distribution of the A2Ars 
in humans using PET and [7-methyl-11C (E)-8-(3, 4, 5-trimethoxystyryl)-1, 3, 7-trimethylxanthine 
([11C] TMSX). The binding potential was largest in anterior and posterior putamen and next largest 
in caudate nucleus and thalamus and small in cerebral cortex (Mishina, et al. 2007). [11C] TMSX-PET 
is a promising PET ligand which can be used to detect diff erences in striatal adenosine receptor 
binding in PD patients compared to controls.
2.4.4 Cardiac sympathetic denervation
Orthostatic hypotension is an early indicator of MSA, but may also occur in advanced stages of 
PD. The underlying pathology of orthostatic hypotension is diff erent in both diseases. In PD, 
orthostatic hypotension is caused primarily by postganglionic sympathetic dysfunction. In MSA 
there is predominantly central and preganglionic degeneration. [123I]-metaiodobenzylguanidine 
(MIBG) binding in SPECT scanning visualizes catecholaminergic terminals and can be used to detect 
cardiac sympathetic degeneration. Reduced uptake of MIBG binding represents postganglionic 
cardiac sympathetic dysfunction which is the case in PD (Nakajima, et al. 2008). Sympathetic cardiac 
uptake in MSA patients is unaff ected (Braune, et al. 1999).  However, studies are not consistent in all 
cases. Some studies report that not all of the parameters of MIBG uptake could discriminate PD from 
MSA and is therefore in early PD patients of limited value  (Chung, et al. 2009, Ishibashi, et al. 2010)
CONCLUSIONS
Presynaptic dopaminergic imaging either with PET or SPECT is the gold standard to diff erentiate 
between patients with parkinsonian features associated with and without a presynaptic 
dopaminergic defi cit. In addition, in order to diff erentiate between PD and other neurodegenerative 
brain diseases, specifi c disease related metabolic patterns identifi ed with FDG-PET imaging could 
be of great assistance in the individual clinical diagnosis. Furthermore there are some promising 
nuclear imaging techniques identifying the cholinergic and adenosine system which in the future 
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The diff erential diagnosis of neurodegenerative brain diseases on clinical grounds is diffi  cult, 
especially at an early disease stage. Several studies have found specifi c regional diff erences of 
brain metabolism applying [18F]-fl uoro-deoxyglucose positron emission tomography (FDG-PET), 
suggesting that this method can assist in early diff erential diagnosis of neurodegenerative brain 
diseases. 
We have studied patients who had an FDG-PET scan on clinical grounds at an early disease stage 
and included those with a retrospectively confi rmed diagnosis according to strictly defi ned 
clinical research criteria. 96 patients could be included of which 20 patients with Parkinson’s 
disease (PD), 21 multiple system atrophy (MSA), 17 progressive supranuclear palsy (PSP), 10 
corticobasal degeneration (CBD), 6 dementia with lewy bodies (DLB), 15 Alzheimer’s disease (AD) 
and 7 frontotemporal dementia (FTD). FDG PET images of each patient group were analysed and 
compared to18 healthy controls using Statistical Parametric Mapping (SPM5). 
Disease-specifi c patterns of relatively decreased metabolic activity were found in PD (contralateral 
parieto-occipital and frontal regions), MSA (bilateral putamen and cerebellar hemispheres), PSP 
(prefrontal cortex and nucleus caudatus, thalamus and mesencephalon), CBD (contralateral cortical 
regions), DLB (occipital and parieto-temporal regions), AD (parieto-temporal regions), and FTD 
(fronto-temporal  regions). 
The integrated method addressing a spectrum of various neurodegenerative brain diseases 
provided means to discriminate patient groups also at early disease stages. Clinical follow up 
enabled appropriate patient inclusion. This implies that an early diagnosis in individual patients 




TYPICAL CEREBRAL METABOLIC BRAIN PATTERNS IN NEURODEGENERATIVE BRAIN DISEASES
3.1 INTRODUCTION
The diff erential diagnosis of neurodegenerative brain diseases may be diffi  cult on clinical grounds 
only. It is important to diagnose these patients early, because prognosis and treatment options diff er 
between neurodegenerative brain diseases. Moreover, accurate diff erential diagnosis is important 
to reduce heterogeneity in pharmacological trials (Litvan et al. 2003). Several neurodegenerative 
diseases have overlapping features at presentation, while the typical clinical syndrome may become 
clear only at later disease stages. 
Neurodegenerative brain diseases that present with parkinsonian features are Parkinson’s disease 
(PD) (Litvan et al. 2003), multiple system atrophy (MSA) (Gilman et al. 2008), progressive supranuclear 
palsy (PSP) (Litvan et al. 1996), corticobasal degeneration (CBD) (Mahapatra et al. 2004) and 
dementia with Lewy Bodies (DLB) (McKeith et al. 2005). Although the pathophysiology and clinical 
progression of these diseases are diff erent, PD, MSA and DLB share the pathological feature of 
disturbed α-synuclein and are designated as α-synucleinopathies (Galpern and Lang. 2006, Gilman 
et al. 2008). Other neurodegenerative brain diseases with parkinsonism show disturbances in tau 
protein handling. PSP and CBD are tauopathies, which points at similarities with frontotemporal 
dementia (FTD) (McKhann et al. 2001) and also overlap in pathology with Alzheimer’s disease (AD) 
(Galpern and Lang. 2006, McKhann et al. 1984). 
The establishment of an exact diagnosis of neurodegenerative brain diseases would benefi t from 
additional tests. Structural imaging is in general not helpful, although specifi c abnormalities can be 
identifi ed at later disease stages. Functional imaging of cerebral glucose metabolism with [18F]-fl uoro-
deoxyglucose positron emission tomography (FDG-PET) provides an index for regional neuronal 
activity. This method has shown diff erences in regional distribution of cerebral glucose metabolism 
for each neurodegenerative brain disease, suggesting that it can assist in early diff erential diagnosis 
(Diehl-Schmid et al. 2007, Eckert et al. 2005, Eckert et al. 2008, Foster et al. 2007, Herholz et al. 2002, 
Jeong et al. 2005, Juh et al. 2004, Klein et al. 2005, Ma et al. 2007a, Minoshima et al. 2001, Mosconi 
et al. 2008, Silverman et al. 2001, Yong et al. 2007). A problem with the general assessment of these 
results is, however, the use of diff erent analysing techniques of regional cerebral FDG uptake and 
inclusion of patients with a more advanced clinical disease stage. Before a generic approach and 
diagnostic consensus for all neurodegenerative brain diseases can be determined, an overview of 
specifi c disease-related metabolic patterns for parkinsonisms and dementias analysed using the 
same image statistical method needs fi rst to be established. The application of disease-specifi c 
metabolic patterns as a reference array for comparison with a single patient dataset will in the end 
be helpful in clinical practice to diagnose individual patients at early disease stages. 
The objective of the present study was to identify distinctive cerebral metabolic patterns at early 
disease stages, in patients with retrospectively confi rmed diagnosis of PD, MSA, PSP, CBD, DLB, AD 
and FTD as compared to healthy controls. Statistical Parametric Mapping (SPM5) and global mean 





All medical records of patients over the past ten years (Jan 1998 till Dec 2008) who were referred for 
FDG-PET imaging to assist in clinical diagnosis of a neurodegenerative brain disease were reviewed. 
At the time of referral for imaging, clinical diagnosis of most patients was uncertain. Disease 
progression over time, after the FDG-PET scan had been performed, allowed an exact diagnosis 
at a later stage. We were able to include patients with a clear retrospective diagnosis according 
to established clinical research criteria which were applied by the investigators LT and KL with a 
follow up time in PD (Litvan et al. 2003) of 4±3 (mean±SD in years) , MSA (Gilman et al. 2008) (2±1), 
PSP (Litvan et al. 1996) (3±2), CBD (Mahapatra et al. 2004) (3±1), DLB (McKeith et al. 2005) (2±1), AD 
(McKhann et al. 1984) (3±2) and FTD (McKhann et al. 2001) (3±1). In total 96 patients were included, 
of which 20 patients with PD (age 63±9 y)  with a Disease Duration (DD) at scanning of 3±2 years. 
Of the 20 PD patients, 6 were predominantly aff ected on the right body side (R) and 14 were left 
body sided aff ected (L). 13 probable MSA-P, one probable MSA-C and 7 possible MSA-P patients 
(age 64±10; DD 4±2) could be included. Furthermore, 13 probable and 4 possible PSP patients (age 
68±8; DD 2±1), 10 CBD patients of whom 7 were right body sided aff ected and 3 left body sided (age 
69±9; DD 2±1, 7R/3L) and 6 DLB patients (age 71±7; DD 3±2) were included. The diagnosis of all 15 
included AD patients (age 65±10; DD 3±2) was corroborated by neuropsychological examination. 
At last 7 FTD patients were included (61±10; DD 3±2). As a control group, 18 healthy controls out of 
an existing database (age 56±14) were included in the study. 
FDG PET data acquisition and image analysis
Patients underwent a static FDG PET scan under standard resting conditions with the eyes closed. 
FDG-PET scans were acquired in a 3D mode after injection of approximately 200 MBq FDG using a 
Siemens ECAT HR+ PET scanner. Patient groups were analysed using SPM5 (Statistical Parametric 
Mapping; Functional Imaging Laboratory (FIL), Wellcome Department of Imaging Neuroscience, 
London, UK) running on Matlab 7.1 (R14, Mathworks Inc.) All reconstructed FDG-PET images were 
spatially normalised onto the dimensions of a standard brain (Montreal Neurological Institute; MNI) 
with voxel sizes of the written normalised images of 1x1x1 mm and default estimation and writing 
options. The normalized images were smoothed using a 10 mm full width at half-maximum (FWHM) 
isotropic Gaussian kernel.  Images of the 6 predominantly right body side aff ected PD patients and 
7 right body side aff ected CBD patients were fl ipped so that all PD and CBD patients had the right 
side of the brain as most aff ected side. 
FDG-PET statistical analysis
Images of each of the seven patient groups were separately compared to controls using a two-
sample t test. The image data were proportionally scaled to the cerebral global mean (the image 
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global mean is calculated as the arithmetical mean of voxels above the threshold of 1/8th of the 
grand mean followed by grand mean scaling to 100) (Yakushev, et al. 2008). Threshold masking was 
set at 0.8 and an explicit mask in MNI space, supplied with SPM5, was added to remove emission 
counts outside the brain. SPM (t) maps were created and regions with a cluster-corrected threshold 
(P< 0.05) and voxels within each cluster (P<0.001) above a Z score of 3.4 will be reported. If clusters 
were adjacent to each other, statistical signifi cance of a cluster was assessed by examining its 
survival at a higher initial voxel threshold.
3.3 RESULTS 
SPM (t) maps were created and overlaid onto a single subject T1 MR template (MNI, SPM5). 
Figure 1 shows regions with decreased metabolic activity, relative to the global mean, in patient 
groups compared to controls and fi gure 2 displays regionally increased metabolic activity, relative 
to the global mean, of patient groups compared to controls. In table 1 and 2 regions with a cluster-
Figure 1: SPM (t) maps of decreased metabolic activity were thresholded at P< 0.001 with cluster cutoff  of 
20 voxels. Patient groups are indicated on the vertical axis and on the horizontal axis, seven transversal slices 
through the brain are shown. 
30
CHAPTER 3
Figure 2:  SPM (t) maps of increased metabolic activity were thresholded at P< 0.001 with cluster cutoff  of 
20 voxels. Patient groups are indicated on the vertical axis and on the horizontal axis, seven transversal slices 
through the brain are shown. 
corrected threshold (P< 0.05) and voxels within each cluster (P<0.001) above a Z score of 3.4 are 
reported. In table 1, each statistical signifi cant region of relatively decreased metabolism in the brain 
is reported for each patient group. Table 2 reports regions with relatively increased metabolism. 
Parkinson’s disease
In PD patients, decreased metabolic activity was seen almost entirely contralateral to the aff ected 
body side, distributed over the prefrontal cortex, anterior cingulate gyrus and a few parietal-
occipital regions. Relatively increased metabolic activity was seen predominantly in a few white 
matter regions including the posterior limb of the internal capsule bilaterally, extending at a relaxed 
threshold (P< 0.05 uncorrected) to the pallidum and posterior putamen contralateral to the aff ected 
body side. Furthermore, increased metabolic activity was seen in cerebellum, pons, contralateral 
hippocampal area and sensorimotor area. 
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Multiple system atrophy
In MSA patients, most prominent decreases in metabolic activity were seen in bilateral putamen and 
cerebellar hemispheres. Furthermore, a decrease was found in the right inferior frontal gyrus, primary 
motor cortex, right angular gyrus, right middle temporal gyrus and calcarine.  Relatively increased 
metabolic activity was seen in a few white matter regions, temporal regions, left sensorimotor area 
and middle occipital gyrus.  
Progressive supranuclear palsy
In PSP patients, a clear pattern of decreased metabolic activity was seen in the whole prefrontal 
cortex, including superior and inferior frontal gyrus, supplementary motor area (SMA), primary 
motor cortex and middle cingulate gyrus. Furthermore, decreased metabolism was found in the 
right caudate nucleus, thalamus and mesencephalon. Relatively increased metabolic activity 
was seen in a few white matter regions, cerebellum, insula, temporo-occipital regions and left 
sensorimotor area. 
Corticobasal degeneration
In the CBD patient group, a strictly unilaterally decreased metabolism was seen in cortical regions, 
contralateral to the aff ected body side, including parieto-temporal regions, prefrontal cortex 
and motor cortex. Furthermore, a decrease was found in the anterior and middle cingulate gyrus 
and a little in the contralateral caudate nucleus and thalamus. Interestingly, relatively increased 
metabolic activity was seen in cortical areas ipsilateral to the aff ected body side, including motor- 
and sensorimotor cortex. In addition, an increased metabolism was found bilaterally in a few white 
matter regions and cerebellar hemispheres. 
Dementia with Lewy Bodies
DLB patients had a marked decrease in metabolic activity in the occipital lobe. In addition, decreases 
were found in parieto-temporal and frontal regions. Relatively increased metabolic activity was seen 
in some white matter regions, thalamus, hippocampus and pons. Such relative increases were also 
seen in the sensorimotor and primary motor cortex, SMA, paracentral lobule and both anterior and 
middle cingulate gyrus. 
Alzheimer’s Disease
In AD patients, most prominent decreases in metabolic activity were found in the angular gyrus 
and other parieto-temporal regions including precuneus extending to the posterior- and middle 
cingulate gyrus. Furthermore, decreases were found in the right middle and inferior frontal gyrus. 
Relatively increased metabolic activity was seen in some white matter regions, cerebellum and 




In FTD patients, decreased metabolic activity was seen in the superior and inferior frontal gyrus, 
anterior cingulate gyrus, SMA, sensorimotor area and middle temporal gyrus. Relatively increased 
metabolic activity was seen a little in occipital, cerebellar and white matter regions. 
3.4  DISCUSSION 
The present study demonstrates a series of typical cerebral metabolic patterns of patients with 
various neurodegenerative brain diseases in a relatively early disease stage using the same statistical 
image analysis for each group. The general features of diff erences in each of the patient groups, 
compared to controls, are consistent with previous studies. However, some interesting diff erences 
can be noted. In Parkinson’s disease, we found a disease-specifi c contralateral cortical decrease 
of metabolic activity, which to our knowledge has not been described before, probably because 
previous studies did not correct for most aff ected body side (Huang et al. 2007a, Ma et al. 2007a). 
One study of Eckert (Eckert et al. 2005)  did fl ip the data according to the most aff ected body side, in 
a small group of early and advanced stage PD. We included 20 PD patients at an early disease stage, 
and this disease-specifi c contralateral cortical decrease could hypothetically be an early marker of 
disease.
We found a distinct disease-specifi c metabolic pattern for MSA, PSP and CBD which is similar to 
the metabolic patterns found for these diseases by the Eidelberg group (Eckert et al. 2005, 2008). In 
neuropathological studies in MSA (Wenning et al. 1997), PSP (Hauw et al. 1994) and CBD (Dickson et 
al. 2002)  the areas described in our study  show neuronal degeneration. Another diff erence which 
explains the decreased striatal metabolic activity in MSA, PSP and CBD and distinguishes these 
diseases from PD is that a postsynaptic striatal neuronal loss is detected post mortem in MSA, PSP 
and CBD and not in PD (Stacy and Jankovic. 1992).
Decreased metabolic activity in occipital regions was the most defi ning feature in DLB patients, 
especially in comparison with AD patients and is consistent with previous imaging studies (Lobotesis 
et al. 2001, Minoshima et al. 2001, Yong et al. 2007). This could be related to the presence of complex 
visual hallucinations which are thought to be useful in distinguishing DLB from other dementias 
(McKeith et al. 2005).
In AD patients, we found expected decreased metabolic activity in parieto-temporal regions, 
corroborating a meta-analysis of  9 studies (AD patients versus controls) which showed  sensitivity 
and specifi city of 86% (Patwardhan et al. 2004). 
More limited metabolic decreases were found  in FTD patients in accordance with previous reports 
(Diehl-Schmid et al. 2007, Jeong et al. 2005). The clinical manifestation of FTD can comprise diff erent 
neuropathological diagnoses at autopsy and if patients die at an early disease stage the brain may 
be unremarkable (Cairns et al. 2007, McKhann et al. 2001).
In our study, global normalisation was applied to improve pattern recognition in the comparisons 
between patient groups. Recently, a discussion was started whether increases of metabolic activity 
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in PD are absolute or only relative i.e. artefactual due to the use of global mean normalization 
(Borghammer et al. 2009b, Grunder et al. 2009, Ma et al. 2009). The use of normalization to the 
global mean is valid if there is no diff erence in global mean values between groups (Grunder et 
al. 2009). Borghammer showed in simulated (15O)-PET images of disease states in control subjects 
that lower global values, even when not statistically signifi cant, led to localized subcortical 
increases in activity following normalization of the data to the global mean. They concluded that 
subcortical hyperactivity emerges as a general phenomenon of global mean normalized studies in 
which increases are then relative to cortical decreases (Borghammer et al. 2009b). Areas that show 
increased metabolic activity may in fact be regarded as most preserved brain regions. However, the 
question remains if this also holds for PD, especially because increased metabolic activity is seen in 
the pallidothalamic regions, which are proposed to be overactive in an absolute sense in PD (Eggers 
et al. 2009, Ma et al. 2009). 
Absolute quantifi cation of FDG-PET data may be the best method to overcome the global mean 
normalization problem. However, that is a time-consuming and demanding procedure, which is 
not feasible in clinical practice. As an alternative for normalization to the global mean, some studies 
have applied normalization to the white matter, pons, cerebellum or sensorimotor cortex (Foster et 
al. 2007, Minoshima et al. 2001, Yakushev et al. 2008). In these regions, we generally found increased 
activity in most of our patient groups, which may provide an argument that these areas are preserved 
and can be used as reference region for normalization. On the other hand, normalization to white 
matter may be not valid because it is not precisely known, whether and how metabolic changes 
occur in white matter in neurodegenerative brain diseases. The pons region is not an optimal 
reference region either, because it is very small and the sensorimotor area is hard to demarcate 
exactly from other brain regions. Cerebellar areas have been used in AD and FTD as reference region. 
However, the use is limited because for example in MSA patients a decreased cerebellar metabolic 
activity can be seen. Recently, Yakushev presented the reference cluster method as alternative 
for global mean normalization (Yakushev et al. 2009). The proposed algorithm normalizes not by 
structure/anatomical region, but rather by the metabolically most preserved part (reference cluster) 
and thus ensures the most eff ective count normalization (Borghammer et al. 2009a, Yakushev et al. 
2009). This method can only be used if metabolic diff erences are expected in one direction. In PD, a 
larger (cortical) reference cluster should then be chosen instead of subcortical or cerebellar, possibly 
hyperactive structures.
Our study was designed to detect distinctive metabolic brain patterns in diff erent typical patient 
groups at early disease stages. These patterns of relatively decreased and relatively increased 
metabolism can help in the diff erential diagnosis. A limitation of the present study is that, despite 
data acquisition of FDG-PET scans over the past ten years, some group samples are still small. 
Nevertheless, it is remarkable that the expected patterns were indeed present in the clinical scans of 
our appropriate patient groups and were clearly distinguishable. Furthermore, healthy controls had 
a younger mean age than some patient groups. An age-dependent global metabolic decrease is 
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well-known (comparing young and eldery subjects with a larger age diff erence) but this is cancelled 
out in the normalization procedure in this study. A major advantage is that typical metabolic brain 
patterns could be determined at early stages of a specifi c disease because we had access to long-
term follow up data of clinical disease progression. At last, statistical analysis of FDG-PET scans using 
SPM5 and global mean normalization is relatively easy. It can be implemented in each center, and 
could therefore be useful in clinical practice. 
Future perspectives
The build up of a database with disease-specifi c patterns, as shown in our study, can be used to 
prospectively compare patients who are clinically still without a clear diagnosis and improve early 
diagnosis in neurodegenerative brain diseases. Furthermore, the newer high resolution PET cameras 
will permit  more reliable absolute quantifi cation of FDG uptake as a marker of neuronal activity in 
small subcortical nuclei which are involved in the pathofysiology of PD (Yakushev et al. 2009). 
3.5 CONCLUSION 
This study reports an overview of specifi c patterns of cerebral metabolic activity with the same 
statistical image analysis technique for conditions with parkinsonism or dementia. Statistical 
analysis of FDG-PET scans using SPM5 and global mean normalization is relatively easy and therefore 
useful in clinical practice. It can assist in early diagnosis of individual patients when each subject’s 
metabolic fi ndings are compared with a database of specifi c disease-related patterns. 
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The diff erential diagnosis of neurodegenerative brain diseases may be diffi  cult on clinical grounds 
only, especially at an early disease stage. Neurodegenerative brain diseases such as Parkinson’s 
disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal 
degeneration (CBD), dementia with Lewy Bodies (DLB), Alzheimer’s disease (AD) and frontotemporal 
dementia (FTD) have overlapping features at presentation, while the typical clinical syndrome 
may become clear only at later disease stages. It is important to diagnose a neurodegenerative 
disease at an early disease stage, because treatment and also the expectancy of future motor or 
cognitive problems diff er between the diseases. It is increasingly recognised that positron emission 
tomography (PET) tracer methods can be used for the measurement of biochemical processes of 
the human brain, to obtain insight in the pathophysiology of brain diseases and to assist in an early 
diagnosis.
Neurodegenerative brain diseases are characterised by cellular malfunction and biochemical 
alterations that occur in early disease stages, before structural brain alterations may become clear. 
Increases and decreases of synaptic activity in the brain are accompanied by proportional changes 
in capillary perfusion and local glucose consumption. Loss of neurons may result in decreased 
glucose consumption in distant brain regions by deaff erentiation, while also increased regional 
glucose consumption by increased activation of aff erent neurons can occur. 
The PET tracer [18F]-fl uorodeoxyglucose (FDG) allows the measurement of glucose consumption. 
FDG is a glucose analog with physiological aspects almost identical to glucose.
FDG-PET imaging has been used intensively to study glucose metabolism and to identify disease-
specifi c cerebral metabolic patterns in several neurodegenerative brain diseases.
Disease-specifi c regional diff erences of brain glucose metabolism have been found in various 
neurodegenerative brain diseases, including parkinsonian syndromes and dementia. This has 
improved our understanding of the pathophysiology of these diseases as well as our ability to 
diagnose patients at an earlier disease stage. Reviewed here are the results of increasing possibilities 
of investigating brain energy metabolism in neurodegenerative brain diseases using FDG-PET with 
univariate and multivariate analysis methods. An overview of specifi c metabolic patterns in several 
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4.1 CEREBRAL GLUCOSE METABOLISM
Increases and decreases of synaptic activity in the brain are accompanied by proportional changes in 
capillary perfusion and local glucose consumption. These changes in glucose consumption are the 
eff ect of changed activity or density of the aff erent nerve terminals in that region. Loss of neurons 
may result in decreased glucose consumption in distant brain regions by deaff erentiation, while 
also increased regional glucose consumption by increased activation of aff erent neurons can occur. 
The PET tracer [18F]fl uorodeoxyglucose (FDG) allows the measurement of glucose consumption. 
FDG is a glucose analog with physiological aspects almost identical to glucose. It is transported 
from the blood to the brain by a carrier-mediated diff usion mechanism. FDG and glucose are 
phosphorylated by hexokinase as the fi rst step of the glycolytic process. FDG diff ers from glucose 
in that a hydrogen atom replaced the hydroxyl group at the second carbon atom of the molecule. 
Glucose is then phosphorylated  to glucose-6-PO4, and continues along the glycolytic pathway for 
energy production. However, FDG is phosphorylated to FDG-6-PO4, which is not a substrate for 
further metabolism and trapped in tissues. As glucose is the only source of energy for the brain it 
refl ects the neuronal integrity of underlying brain pathology. Since FDG is a competitive substrate 
with glucose for both transport and phosphorylation, it is important for tracer uptake to avoid high 
blood glucose levels during an FDG-PET scan in subjects with diabetes. 
In neurodegenerative brain diseases, specifi c brain regions degenerate and specifi c patterns 
of metabolic brain activity develop. This happens before clear structural changes can be detected 
with imaging techniques. Measurement of glucose consumption with FDG-PET imaging thus allows 
us to identify disease-specifi c cerebral metabolic brain patterns in several neurodegenerative 
brain diseases at  an early disease stage. Since the fi rst FDG-PET study in man in 1979 (Reivich 
et al. 1979) regional diff erences in cerebral glucose metabolism have been reported in various 
neurodegenerative brain diseases including parkinsonian syndromes.  
4.2 DISEASE-SPECIFIC METABOLIC BRAIN PATTERNS: METHODS
Univariate methods like voxel-based statistical parametric mapping (SPM) analyses have been used 
to identify group diff erences between patients with neurodegenerative brain diseases and controls 
(Eckert et al. 2005, Juh et al. 2004, Yong et al. 2007). 
At the University Medical Center Groningen, The Netherlands, we have performed a retrospective 
study (Teune et al. 2010) selecting typical patients with 7 diff erent neurodegenerative brain diseases 
who had had a clinical FDG brain scan at a time point when their diagnosis was not sure yet. These 
patients developed in the following years the mentioned typical disease states. Images of each of 
the seven patient groups were separately compared to controls using a two-sample t test. At those 
early scans, already typical diff erences between patient groups and healthy controls were found for 
each disease. 
However, Scaled Subprofi le modelling/principal component analysis (SSM/PCA), a multivariate 
method, not only identifi es group diff erences, but is also able to identify relationships in relatively 
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increased and decreased metabolic activity between diff erent brain regions in combined samples of 
patients and control scans (Eidelberg 2009, Moeller et al. 1987). Covariance analysis techniques are 
considered appropriate methods to explore network activity. In the SSM, a threshold of the whole-
brain maximum can be applied to remove out-of-brain voxels, followed by a log transformation. A 
threshold of 35% is used by the Eidelberg research group resulting in a mask of mainly grey matter 
(Spetsieris and Eidelberg 2010). After removing between-subject and between-region averages, a 
principal component analysis (PCA) can be applied. PCA transformes a set of correlated variables 
into a new set of orthogonal uncorrelated variables that are called the principal components. Voxels 
participating in each principal component (PC) may have either a positive or a negative loading. 
The loadings express the covariance structure (i.e. the strength of the interaction) between the 
voxels that participate in the PC. They are ordered in terms of the variability they represent. That 
is, the fi rst principal components represents for a single dimension (variable) the greatest amount 
of variability in the original dataset. Each succeeding orthogonal component accounts for as much 
of the remaining variability as possible. They can be very helpful in determining how many of the 
components are really signifi cant and how much the data can be reduced. 
In most studies, the components that together describe at least 50% of the variance are 
used for further analysis, but this is an arbitrary limit. To identify a covariance pattern that best 
discriminates a patient group from a control group, each subject’s expression of the selected 
principal components with the lowest AIC (Akaike information criterion) value (Akaike 1974) are 
entered into a stepwise regression procedure. This regression results in a linear combination of the 
PCs that best discriminated the two groups and is designated as the disease-specifi c metabolic 
covariance pattern. 
Important for its use in clinical practice is that this metabolic covariance pattern can then be applied 
to individual patients to test whether they express the pattern or not. Every voxel value in a subject 
scan is multiplied by the corresponding voxel weight in the covariance pattern, with a subsequent 
summation over the whole brain volume. The resulting subject score captures to what extent a 
subject expresses the covariance pattern. 
4.3 DISEASE-SPECIFIC METABOLIC BRAIN PATTERNS IN PATIENTS WITH PARKINSONISM.
4.3.1 Parkinson’s Disease
Parkinson’s disease (PD) is characterized by bradykinesia, rigidity, sometimes rest tremor and postural 
instability. A disturbed α-synuclein protein forming so-called Lewy bodies seems to play a causal 
role, which was a reason to designate PD as a α-synucleinopathy.  The main pathophysiological 
changes result from degeneration of catecholaminergic, especially dopaminergic cells in brainstem 
regions. 
A characteristic metabolic covariance pattern has been identifi ed in PD patients (PD-related 
pattern, PDRP) showing regionally relatively increased metabolism in the globus pallidus and 
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putamen, thalamus, pons and cerebellum and relatively decreased metabolism in the lateral 
frontal, premotor and parietal association areas (Ma, et al. 2007b) Network expression in PD patients 
also increases linearly with disease progression (Huang, et al. 2007c). Tang tried to study network 
changes in the PD-related motor pattern before symptom onset by studying 15 hemiparkinsonian 
patients and focusing mainly on the “presymptomatic” hemisphere. They conclude that abnormal 
PDRP activity antecedes the appearance of motor signs by approximately 2 years (Tang et al. 2010a). 
However, this needs to be proven in future research in true presymptomatic patients.
Parkinson’s Disease and metabolic brain patterns related to specifi c symptoms
In addition to motor symptoms, cognitive dysfunction is also common in PD, especially executive 
and visuospatial dysfunction. FDG-PET studies have been performed to study these specifi c 
symptoms and their relations with neural network pathophysiology. The Eidelberg research group 
has shown PD subclassifi cations related to specifi c symptoms. Network analysis with the SSM/PCA 
approach detected a signifi cant covariance pattern in non-demented PD patients that correlated 
with memory and executive functioning tasks. The expression of this PD-related cognitive pattern 
(PDCP)  in individual patients correlated with severity of cognitive dysfunction (Huang et al. 2007b). 
Alterations in neuropsychological test results in advanced PD were found to correlate with 
decreases in glucose metabolism in the dorsolateral prefrontal cortex, lateral orbitofrontal cortex 
ventral and dorsal cingulum and in Broca area (Kalbe et al. 2009). In the study of Kalbe, PD patients 
with deep brain stimulation in the subthalamic nucleus (STN-DBS) showed cognitive decline that 
correlated with decrease in glucose metabolism in these areas. In another study in STN-DBS treated 
patients, STN-DBS was found to activate glucose metabolism in the frontal limbic and associative 
territory (Hilker et al. 2004). Interestingly, cortical areas that show hypometabolism in patients with 
depression (Mayberg HS. 1994) are similar to the regions that show restored glucose metabolism 
after STN-DBS. This fi nding agrees with the clinical observation that PD-related depression tends to 
improve after STN- DBS.
Mure identifi ed a spatial covariance pattern associated with Parkinson tremor which was 
characterized by covarying increases in the cerebellum/dentate nucleus and primary cortex and to 
a minor degree in the caudate/putamen (Mure et al. 2011). 
Hallucinations in PD have been related to relative frontal hypermetabolism compared to PD patients 
without hallucinations (Nagano-Saito et al. 2004). However, another study showed hypometabolism 
in occipitotemporoparietal regions in PD patients with hallucinations, sparing the occipital pole, 
while no signifi cant increase in regional glucose metabolism was detected (Boecker et al. 2007). 
Interestingly, in patients with dementia with Lewy bodies (DLB), who also suff er from hallucinations, 
glucose metabolism was also decreased in occipitoparietal regions, however without sparing of the 
occipital pole (see DLB section). 
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4.3.2 Multiple system atrophy 
Multiple system atrophy is a sporadic neurodegenerative brain disease which aff ects both men and 
women and generally starts in the sixth decade of life. The main clinical features are parkinsonism, 
autonomic failure, cerebellar ataxia, and pyramidal signs in any combination. However, two major 
motor presentations can be distinguished. Parkinsonian features predominate in 80% of patients 
(MSA-P subtype) and cerebellar ataxia is the main motor feature in 20% of patients (MSA-C subtype) 
(Gilman et al. 2008, Wenning et al. 1997). 
In MSA-P the striatonigral system is the main site of pathology but less severe degeneration can be 
widespread and normally includes the olivopontocerebellar system. In MSA-C pathological changes 
are mainly seen in the olivopontocerebellar system and involvement of striatum and substantia 
nigra are less severe (Wenning et al. 1997). The discovery of glial cytoplasmic inclusions in MSA 
brains highlighted the unique glial pathology as biological hallmark of the disease. Their distribution 
selectively involves basal ganglia, supplementary and primary motor cortex, the reticular formation 
and pontocerebellar system. Glial cytoplasmic inclusions contain besides classical cytoskeletal 
antigens also α-synuclein, which is a presynaptic protein present in Lewy Bodies, and this 
accumulation seems to play a central part not only in MSA but also in other α-synucleinopathies 
such as PD and DLB. 
Disease-related metabolic patterns were also present in MSA consisting of hypometabolism in 
putamen and cerebellum in MSA (Eckert et al. 2008). Poston found that diff erences in expression of 
the MSA-related pattern correlated with clinical disability (Poston et al. 2012). 
4.3.3 Progressive supranuclear palsy
The clinical picture of progressive supranuclear palsy (PSP) has been fi rst described by Steele, 
Richardson and Olszewski (Steele JC, Richardson J,Olszewski J. 1964) and is characterized by 
progressive parkinsonism, early gait and balance impairment, vertical gaze palsy and more profound 
frontal cognitive disturbances. PSP is one of several neurodegenerative diseases characterised by 
accumulation of hyperphosphorylated tau (tauopathy), forming abnormal fi lamentous inclusions in 
neurons and glia in the precentral and postcentral cortical areas but also in the thalamus, subthalamic 
nucleus, red nucleus and substantia nigra. Other neurodegenerative brain diseases which show 
disturbances in tau protein handling are corticobasal degeneration (CBD) and frontotemporal 
dementia (FTD) but there is also overlap in pathology with Alzheimer’s disease (AD).
However, the metabolic brain patterns in these tauopathies are quite diff erent. The covariance 
pattern of PSP consists of decreased metabolism in the prefrontal cortex, frontal eye fi elds, caudate 
nuclei, medial thalamus and upper brainstem (Eckert et al. 2008). Brain stem atrophy and atrophy 
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4.3.4 Corticobasal Degeneration
The most striking features of patients with corticobasal degeneration (CBD) include marked 
asymmetrical parkinsonism and apraxia but also postural instability, limb dystonia, cortical sensory 
loss, dementia and the alien limb phenomenon. CBD is one of the tauopathies and 
clinical diagnosis is complicated by both the variability of presentation of true CBD and the 
syndromes that look alike but are caused by other tauopathies with parkinsonism like PSP or FTD 
(Josephs et al. 2006). However with functional neuroimaging a clear distinction can be made. In 
CBD, a typical pattern of hypometabolism is seen in cortical regions contralateral to the aff ected 
body side, including parieto-temporal regions, prefrontal cortex and motor cortex. Furthermore, 
a decrease can be found in the contralateral caudate nucleus, putamen and thalamus (Eckert et al. 
2005, Teune et al. 2010). No covariance pattern has been described using the SSM/PCA technique 
in CBD.
4.4 DISEASE-SPECIFIC METABOLIC BRAIN PATTERNS IN THE DIFFERENTIAL DIAGNOSIS OF 
INDIVIDUAL PATIENTS WITH PARKINSONISM.
Interestingly, Tang and co-workers studied the potential role of FDG PET in the individual diagnosis 
of 167 patients who had parkinsonian features but uncertain clinical diagnosis (Tang et al. 2010b) 
After FDG-PET imaging, patients were assessed by blinded movement disorders specialists for a 
mean of 2.6 years before a fi nal clinical diagnosis was made (gold standard). SSM/PCA analysis can 
quantify the expression of an obtained covariance pattern in each subject which allows assessing 
the expression of a given pattern on a single case basis. Using this automated image-based 
classifi cation procedure and the previously defi ned disease-related covariance patterns in PD, MSA 
and PSP, individual patients were diff erentiated with high specifi city. 
However, blinded, prospective imaging studies (ideally involving multiple centers, a larger validation 
group, repeat imaging, and more extensive post-mortem confi rmation) are needed to establish the 
accuracy and precision of this pattern-based categorisation procedure. These studies are currently 
undertaken.
For routine clinical practice, this knowledge of disease-specifi c patterns of regional metabolic 
activity in neurodegenerative brain diseases can be a valuable aid in the diff erential diagnosis of 
individual patients, especially at an early disease stage. 
4.5 DISEASE-SPECIFIC METABOLIC BRAIN PATTERNS IN DEMENTIA.
4.5.1 Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive neurodegenerative brain disease accounting for 50-
60% of cases of dementia. AD is characterized by a severe decline in episodic memory together 
with general cognitive symptoms such as impaired judgement, decision making and orientation 
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(McKhann et al. 1984).  A correct clinical diagnosis can be diffi  cult, especially in early disease stages 
or in patients with for example comorbid depression, high education or young age (Bohnen et al. 
2012). FDG-PET imaging can be used to assist in the diff erential diagnosis, because for diff erent 
dementia syndromes, a separate pattern of hypometabolism can be found. In Alzheimer’s disease 
(AD), decline of FDG uptake in posterior cingulate, temporoparietal and prefrontal association 
cortex was related to dementia severity (Herholz et al. 2002). Foster used visual interpretation of 
an automated three-dimensional stereotactic surface projection technique of patients with AD and 
FTD. They showed that visual interpretation of FDG-PET scans after training is more reliable and 
accurate in distinguishing FTD from AD than clinical methods alone (Foster et al. 2007). 
Although multivariate analytical techniques might identify diagnostic patterns that are not captured 
by univariate methods, they have rarely been used to study neural correlates of Alzheimer’s 
Disease or cognitive impairment. Because cognitive processes are the result of integrated activity 
in networks rather than activity of any one area in isolation, functional connectivity can be better 
captured by multivariate methods. A study from Habeck examined the effi  cacy of multivariate and 
univariate analytical methods and concluded that multivariate analysis might be more sensitive 
than univariate analysis for the diagnosis of early Alzheimer’s disease (Habeck et al. 2008).
Scarmeas et al were the fi rst to derive an AD-related covariance pattern using H2
15O to measure 
brain perfusion (Scarmeas et al. 2004). It consisted of relatively increased perfusion in the bilateral 
insula, lingual gyri and cuneus with bilaterally decreased fl ow in bilateral inferior parietal lobule 
and cingulate in AD patients. However, using this PET tracer they found a sensitivity of 76-94% and 
a specifi city of 63-81% with considerable overlap in pattern expression among AD patients and 
controls. Therefore they concluded that the derived H2
15O pattern cannot be used as a suffi  cient 
diagnostic test in clinical settings. Specifi c FDG covariance patterns to distinguish early AD-related 
cognitive decline using multivariate methods have yet to be specifi ed.
4.5.2 Frontotemporal dementia
Frontotemporal dementia (FTD) is one of the neurodegenerative diseases commonly mistaken 
for AD. FTD patients do not have a true amnestic syndrome but can present with either gradual 
and progressive changes in behaviour, or gradual and progressive language dysfunction. Gross 
examination of the post-mortem brain from a patient with FTD usually reveals frontal or temporal 
lobar atrophy or both, but the distribution or severity of brain atrophy are not specifi c for a particular 
neurodegenerative brain disease. Jeong and Diehl-Schmid analysed FDG-PET scans of FTD patients 
on a voxel-by-voxel basis using Statistical Parametric Mapping (SPM). They found hypometabolism 
depending on disease stage in the frontal lobe, parietal and temporal cortices (Diehl-Schmid et al. 
2007, Jeong et al. 2005). 
4.5.3 Dementia with Lewy Bodies
The clinical overlap of dementia and parkinsonism is highlighted in Dementia with Lewy Bodies 
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(DLB). These patients show besides dementia extrapyramidal motor symptoms and marked 
neuropsychiatric disturbances including visual hallucinations, depression, variability in arousal and 
attention (McKeith 2006). Consistent observation of a metabolic reduction in the medial occipital 
cortex in DLB patients (Minoshima et al. 2001, Teune et al. 2010) using FDG-PET imaging suggests 
the use of FDG-PET in the diff erential diagnosis of AD and DLB and of PD and DLB. Minoshima found 
that the presence of occipital hypometabolism distinguished DLB from AD with 90% sensitivity and 
80% specifi city when using post-mortem diagnosis as the gold standard diagnosis (Minoshima et 
al. 2001). 
4.6 DISEASE-SPECIFIC METABOLIC BRAIN PATTERNS IN HYPERKINETIC MOVEMENT 
DISORDERS
4.6.1 Huntington’s disease
Huntington’s disease (HD) is characterized by progressive dementia and chorea, starting around 
30-40 years of age. HD is caused by a dominantly inherited CAG repeat expansion mutation that 
generates lengthening of the protein huntingtin, with size-dependent neurotoxicity. Several 
PET studies have shown hypometabolism in the caudate nucleus, both in symptomatic and 
asymptomatic mutation carriers (Grafton et al. 1992) (Antonini et al. 1996) In asymptomatic carriers, 
metabolic decreases were also signifi cantly associated with the CAG repeat number (Antonini et 
al. 1996). Furthermore, it was found that FDG uptake in the caudate nucleus provided a predictive 
measure for time of onset of the disease, in addition to the mutation size (Ciarmiello et al. 2012).
Another study applied network analysis of FDG-PET scans in presymptomatic mutation carriers 
(Feigin et al. 2001). They found a HD-related metabolic covariance pattern (HDRP) characterized 
by caudate and putaminal hypometabolism, but also including mediotemporal reductions as well 
as relative increases in occipital regions. Disturbances of these striatotemporal projections may 
underlie aspects of the psychiatric and cognitive abnormalities that occur in the earliest stages of 
HD, before the onset of motor signs (Cummings. 1995).
4.6.2 Dystonia
Dystonia is a movement disorder characterized by involuntary, sustained muscle contractions 
causing twisting movements and abnormal postures. The most common forms of primary torsion 
dystonia (PTD) are DYT1 and DYT6, both caused by  autosomal inherited mutations with a reduced 
penetrance. 
Functional neuroimaging techniques have been applied in diff erent dystonic disorders including 
primary generalized dystonia, mainly DYT1 and DYT6 and dopa-responsive dystonia, as well as focal 
dystonic syndromes such as torticollis, writer’s cramp and blepharospasm. A common fi nding is 
abnormality of the basal ganglia, cerebellum and associated outfl ow pathways to sensorimotor 
cortex and other regions involved with motor performance. However, controversial results have 
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been found in imaging dystonias, partly attributed to methodological diff erences but also to the 
heterogeneity of the dystonias. Using the SSM/PCA approach a reproducible pattern of abnormal 
regional glucose utilization in two independent cohorts of DYT1 carriers have been found (Eidelberg 
1998, Trost et al. 2002). This torsion-dystonia related metabolic pattern is characterized by increases 
in the posterior putamen/globus pallidus, cerebellum and SMA. Interestingly, also in clinically non-
manifesting mutation carriers this pattern was found, suggesting a cerebral “vulnerability to develop 
dystonia” network change. Also in manifesting and non-manifesting DYT 6 carriers abnormal 
network activity has been identifi ed. A diff erence between DYT1 and DYT6 metabolic patterns can 
be seen in the putamen, where glucose metabolism is increased in DYT1 and decreased in DYT6, 
possibly due to cell loss in DYT6. Furthermore, the cerebellum shows increased activity in DYT1 and 
normal activity in DYT6 (Carbon et al. 2004).
The TDRP network is not expressed in patients with Dopa-responsive dystonia (DRD) (Trost et al. 
2002).
DRD is characterized by an early onset of dystonic symptoms and later appearance of 
parkinsonian symptoms. A defi ning feature is a marked and sustained response to low doses of 
levodopa, suggesting that the lesion may be functional in the presynaptic dopaminergic system 
rather than anatomical. The DRD-related metabolic pattern is characterized by relative increases in 
the dorsal midbrain, cerebellar vermis and SMA, assiocated with covarying decreases in putamen, 
lateral premotor and motor cortical regions (Asanuma et al. 2005). This DRD-related pattern is not 
apparent in DYT 1 and 6 carriers supporting the hypothesis that the pathophysiology of DRD diff ers 
from that of other forms of dystonia. They also found that the Parkinson-related metabolic pattern is 
not apparent in DRD patients.  Thus FDG-PET can be useful to distinguish PD-related dystonia from 
dopa-responsive dystonia with parkinsonism (Asanuma et al. 2005). 
4.6.3 Gilles de la Tourette 
Tourette syndrome is characterized by the presence of chronic motor and vocal tics that develop 
before the age of 18. Comorbid behavioural abnormalities are common in Tourette syndrome, 
most notably obsessive-compulsive disorder and attention defi cit/hyperactivity disorder (Lebowitz 
et al. 2012). The neurophysiology remains poorly understood with varying and inconsistent 
neuropathological and neuroimaging fi ndings, possibly due to the clinical heterogeneity of the 
disorder. Pourfar identifi ed a Tourette syndrome related pattern characterized by reduced metabolic 
activity of the striatum and orbitofrontal cortex associated with relatively increased metabolic 
activity in the premotor cortex and cerebellum (Pourfar et al. 2011). A second metabolic brain pattern 
was found in patients with Tourette syndrome and obsessive compulsive disorder characterized by 
reduced activity in the anterior cingulate and dorsolateral prefrontal cortex and relative increases in 
primary motor cortex and precuneus. Subject expression correlated with symptom severity. These 
fi ndings  suggest that the diff erent clinical manifestations of the Tourette syndrome are associated 
with diff erent abnormal brain networks (Pourfar, et al. 2011).
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4.7 CONCLUSION
FDG-PET imaging is increasingly available for routine clinical practice and has remained the only 
available radiotracer to detect accurately and reliably the cerebral glucose metabolism. As glucose 
is the only source of energy for the brain it refl ects the energy needs of underlying brain neuronal 
systems. The SSM/PCA method can identify relationships in relatively increased and decreased 
metabolic activity between diff erent brain regions in combined samples of patients and controls. 
The expression of a covariance pattern can be quantifi ed in an individual patient. The obtained 
subject score indicates to what extent that patient expresses the disease-related pattern. These 
metabolic brain patterns can therefore be a valuable aid in the diff erential diagnosis of individual 
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Objective: To validate disease-related metabolic brain patterns for Parkinson’s Disease,
multiple system atrophy and progressive supranuclear palsy.
Methods: The study included twenty Parkinson´s Disease, twenty one with multiple system 
atrophy and seventeen progressive supranuclear palsy: all of whom had undergone a clinically 
motivated [18F]-fl uoro-deoxyglucose positron emission tomography scan at an early stage of their 
disease. At a follow up time after the scan of 2-4 years, a clinical diagnosis was made according to 
established clinical research criteria. Patient groups were compared to eighteen healthy controls 
using a multivariate covariance image analysis technique called scaled subprofi le model/principal 
component analysis (SSM/PCA).
Results: Disease-related metabolic brain patterns for these parkinsonian disorders were
identifi ed. Validation showed that these patterns were highly discriminative of the three disorders.
Conclusion: Early diagnosis of parkinsonian disorders is feasible when the expression of disease-
related metabolic brain patterns is quantifi ed at single-subject level. 
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5.1 INTRODUCTION
Visual examination of [18F]-fl uoro-deoxyglucose positron emission tomography (FDG-PET) scans 
may guide the diff erential diagnosis of parkinsonian syndromes. Nevertheless, interpretation 
of both clinical symptoms and FDG-PET scans can be diffi  cult. Previously, univariate methods 
like statistical parametric mapping (SPM) have been used to identify group diff erences between 
parkinsonian patients and controls (Eckert et al. 2005, Juh et al. 2004, Teune et al. 2010). However, 
scaled subprofi le modelling/principal component analysis (SSM/PCA), a multivariate method, not 
only identifi es group diff erences, but also relationships in metabolic activity between diff erent brain 
regions in combined samples of patients and control scans (Moeller and Strother. 1991, Spetsieris 
et al. 2009). A Parkinson’s disease-related metabolic pattern was characterized by relative increases 
in pallidothalamic, pontine and cerebellar metabolism and relative decreases in the premotor and 
posterior parietal areas while typical disease-related metabolic patterns have also been identifi ed 
for multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) (Eckert et al. 2008, Ma 
et al. 2007b, Poston et al. 2012). SSM/PCA additionally enables quantifying the magnitude of the 
expression of a network for individual subjects (subject score) thus facilitating clinical investigation 
at single-subject level (Spetsieris and Eidelberg. 2010).
Recently, Tang highlighted the diagnostic value of FDG PET in parkinsonian patients with diagnostic 
uncertainty, by discriminating between Parkinson’s disease (PD), MSA and PSP with high specifi city 
using an automated image-based classifi cation procedure (Tang et al. 2010b). Since all previously 
mentioned papers on SSM/PCA-processed FDG-PET data originate from one research group, the 
present study aimed to validate these patterns in other cohorts, which is an essential prerequisite 
before routine clinical application. Therefore, specifi city and sensitivity of disease-related metabolic 
patterns for PD, MSA and PSP were assessed in our own patient population.
5.2 METHODS
Patients 
FDG-PET scans selected from a previous study (Teune, et al. 2010) describing 18 healthy controls 
and 20 PD, 21 MSA, 17 PSP patients were included for the present analysis. At the time of referral for 
imaging, the clinical diagnosis of most patients was uncertain. The fi nal clinical diagnoses according 
to established clinical research criteria (Gilman, et al. 2008, Litvan, et al. 1996, Litvan, et al. 2003) 
were made after a follow up time after scanning of 4±3 years (y) in PD, 2±1y in MSA and 3±2y in PSP. 
Included PD patients were 9 male (M), 11 female (F), 6 right body-side aff ected, 14 left-side aff ected, 
with mean age of 63±9y and Disease Duration (DD) at scanning of 3±2 years. Fourteen probable 
MSA, 7 possible MSA patients (10M, 11F, age 64±10y; DD 4±2y) and 13 probable, 4 possible PSP 
patients (9M, 8F, age 68±8y; DD 2±1y) were included. 
52
CHAPTER 5
FDG-PET data acquisition and statistical analysis
Patients were scanned on a Siemens ECAT HR+ PET scanner in a 3D mode under standard resting 
conditions (eyes closed) after injection of approximately 200 MBq FDG in 4ml saline. Reconstructed 
FDG-PET images were spatially normalised to a standard brain PET template (Montreal Neurological 
Institute; MNI) using SPM8 (Functional Imaging Laboratory, running in Matlab 7.10.0 (R2010a, 
Mathworks)) and smoothed with a 10mm full width at half-maximum isotropic Gaussian kernel. 
SSM/PCA was applied using software written in-house, based on the methods of Spetsieris and 
Eidelberg (Eidelberg. 2009, Spetsieris and Eidelberg. 2010). A 35% threshold of the whole-brain 
maximum was applied to remove out-of-brain voxels which results in a mask of mainly grey matter, 
followed by a log transformation. After removing between-subject and between-region averages, 
a principal component analysis (PCA) was applied. All components that together described at 
least 50% of the variance were used for further analysis. A disease-related metabolic covariance 
pattern was determined by a linear combination of the selected principal components with the 
lowest AIC (Akaike information criterion) value (Akaike. 1974) in a stepwise regression procedure. 
The correctness of the in-house written script was verifi ed by performing the analysis both with the 
Eidelberg software and our own software, which provided identical results.
Without a second patient group for pattern validation (Spetsieris et al. 2010), a leave-one-out 
cross validation procedure was performed, resulting in subject scores independent from the pattern 
identifi cation step. Subject scores were transformed into z-scores with respect to the healthy control 
population and displayed, for each comparison separately, in a scatter plot. 
Receiving-operating-characteristic (ROC) curves were determined for the probability values of PD, 
MSA and PSP. Optimum cut-off  probability values for classifying individual patients were calculated 
by identifying an infl ection point on each ROC curve that corresponds to the best combination 
of sensitivity and specifi city. Patients were classifi ed as correctly diagnosed if their probability 
value was higher than the cut-off  value. Thereafter, we calculated for each comparison sensitivity, 
specifi city, and positive- and negative predictive value (PPV and NPV respectively). 
In addition to obtaining valid subject scores, the leave-one-out procedure provides an estimate 
of the disease-related metabolic brain patterns and their variances. Dividing the estimate by its 
variance a T-score is obtained. Resulting patterns are thresholded at T>3.7 (corresponding to 
p<0.001, assuming normality of data) and overlaid onto a T1 MR template using MRIcron. 
5.3 RESULTS
Spatial covariance analysis was performed on FDG-PET scans from PD, MSA and PSP patients. 
The model with the lowest AIC value (Akaike. 1974) was determined by a linear combination of 
PC (principal component) number 1,4,5 with variance accounted for (VAF) of 26.73% for PD;  PC 
1,2,4 (33.91% VAF) for MSA and PC 1 and 5 (26.30% VAF) for PSP. A leave-one-out cross validation 
procedure was subsequently performed, generating disease-related metabolic patterns (Figure.1) 
and scatter plots with corresponding ROC curves (Figure.2).
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The PD-related metabolic covariance pattern was characterized by relative metabolic decreases, 
especially contralateral to the aff ected body side in most patients, comprising the (posterior) 
parietal association cortex, visual cortex, lateral premotor and prefrontal association cortex. Relative 
increases were seen in the pons, bilateral thalamus, pallidum, dorsal putamen, primary motor 
cortex and supplementary motor area. Their corresponding z-scores showed an overlap between 
the patients and healthy controls using the PD-related metabolic pattern. A cut-off  value of z=0.45 
Figure 1: (T) maps of metabolic brain patterns were overlaid on a T1 MR template. Relative metabolic decreases 
(blue) and increases (red) compared to the control group are thresholded at T= 3.7-6.7 (P< 0.001). Patient groups 
are indicated on the vertical axis and on the horizontal axis seven transversal slices through the brain are shown. 
Figure 2: Scatter plot and ROC curves for each comparison. On the Y-axis the leave-one-out z-scores are dis-
played and on the X-axis the group comparisons. Receiving-operating-characteristic (ROC) curves were plotted 
for each comparison separately. * = infl ection point (z-score); Y-axis= sensitivity, X-axis= 1-specifi city; PPV = posi-
tive predictive value; NPV = negative predictive value. 
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resulted in a sensitivity of 80% and specifi city of 77.8% for correct PD classifi cation of an individual 
patient.
The MSA-related metabolic covariance pattern was characterized by relative metabolic decreases 
bilaterally in the putamen and caudate nucleus with minor decreases in the premotor and primary 
visual cortex on the right side. At a lower threshold (p<0.05) metabolic decreases were  seen in 
the cerebellum (data not shown). Relative increases were seen in the subcortical white matter and 
mid-temporal cortex. Their corresponding z-scores showed less overlap between the patients and 
healthy controls and at a cut-off  value of z=0.65, the MSA-related metabolic pattern had a sensitivity 
of 90.5% and specifi city of 83.3%. A direct comparison between PD and MSA patients, which is 
clinically relevant, improved specifi city to 90%.
The PSP-related metabolic covariance pattern was characterized by relative metabolic decreases 
bilaterally in prefrontal cortex regions, cingulate cortex, frontal eye fi elds and minor decreases in 
the posterior parietal association cortex, caudate nucleus, ventral putamen and cerebellum crus. At 
a lower threshold (p<0.05) metabolic decreases were seen in thalamus and mesencephalon (data 
not shown). Relative increases were seen in the inferior- and mid-temporal cortex, subcortical white 
matter, sensorimotor cortex, pons and vermis.  
The PSP-corresponding z-scores showed virtually no overlap with healthy controls. Using the PSP-
related metabolic pattern at a cut-off  value of z=0.94, sensitivity was 82.4% and specifi city of 100% 
(Figure.2).
5.4 DISCUSSION 
Metabolic covariance patterns for PD, MSA and PSP obtained by SSM/PCA and leave-one-out 
cross validation in our patients were in agreement with previous studies (Eckert et al. 2008, Ma et 
al. 2007a). These patterns showed high sensitivity and specifi city, supporting that these image-
based classifi cations may improve clinical practice concerning diagnosing individual parkinsonian 
patients. 
High stability and reproducibility of these metabolic covariance patterns was previously suggested 
by respectively a region-defi ned approach (Moeller et al. 1999), a test-retest design (Ma et al. 2007a) 
and in a cross-validation approach (Spetsieris et al. 2010), all by the same research group. This is now 
confi rmed by the present study. 
The next step is to prove the value in clinical practice. Tang et al have already demonstrated an 
image-based classifi cation routine with high specifi city to distinguish between parkinsonian 
patients (Tang et al. 2010b). In our present study we showed that the “simple” comparison between 
healthy controls and patient groups already yielded a high sensitivity and specifi city for correctly 
classifying PD, MSA or PSP patients. Especially specifi city increased by directly comparing PD 
and MSA, which is relevant because the clinical motivation for a FDG-PET originates from doubts 
between PD or MSA, not between healthy or PD. 
The current clinical diagnosis is made by expert movement disorder specialists, although 
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neuropathological confi rmation is considered to be more accurate. However, Hughes concluded 
that in case of a thorough examination made by expert movement disorder specialist using clinical 
research criteria and a suffi  cient follow up period, a sensitivity of 91.1% for PD, 88.2% for MSA and 
84.2% for PSP compared to neuropathological examination can be found (Hughes et al. 2002). In 
general neurological practice, diagnostic accuracy is around 76% (Hughes et al. 1992). Therefore, the 
metabolic brain pattern results, obtained at early disease stage, represent high values of specifi city 
and sensitivity and are especially benefi cial in the early diff erential diagnosis of parkinsonian 
patients.
Further data inclusion will increase sensitivity and specifi city of the listed metabolic brain 
patterns and will enable subclassifi cations in for example left/right body-side aff ected patients. 
The Eidelberg research group has already shown PD subclassifi cations related to specifi c symptoms 
(tremor, cognition) (Huang et al. 2007a, Mure et al. 2011, Poston and Eidelberg. 2009). Application 
of this method may also be useful for other parkinsonian and dementia syndromes to enhance 
diagnostic precision. This puts forward a research challenge to improve the SSM/PCA method. 
Regarding previous suggestions to select components used for creating a disease-related metabolic 
pattern (Spetsieris and Eidelberg. 2010), one might consider machine learning approaches like 
decision-tree methods to improve sensitivity and specifi city (Quinlan. 1993).
5.6 CONCLUSION 
The applied image-based classifi cations imply that an early diagnosis is feasible by quantifying the 
magnitude of the expression of diff erent disease-related metabolic brain patterns through subject 
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Introduction: [18F]fl uorodeoxyglucose (FDG) PET imaging of the brain can be used to assist in 
the diff erential diagnosis of dementia. Group diff erences in regional cerebral glucose utilisation 
of patients with dementia compared to controls are well-known. However, multivariate analysis 
techniques aiming at identifying diagnostic neural networks in diseases, have been applied less 
frequently. The aim of this study was to present and validate an Alzheimer’s disease-related (AD) 
glucose metabolic brain pattern and to apply it prospectively in a second cohort of individual 
patients with memory complaints. 
Methods: As a fi rst step, we used a multivariate analysis technique (scaled subprofi le model, 
principal component analysis (SSM/PCA)) to identify an AD-related glucose metabolic covariance 
pattern  in 18 healthy controls and 15 AD patients (identifi cation cohort). The stability of the results 
was evaluated by a leave-one-out cross validation. 
Next, we investigated the ability of the identifi ed AD-related metabolic covariance pattern 
to discriminate between probable AD and non-probable AD (possible AD, mild cognitive 
impairment (MCI) or subjective complaints) and the association of the metabolic patterns with 
neuropsychological tests. This part of the study was done in an independent cohort of 15 patients 
referred to our memory clinic (confi rmation cohort). Pattern expression was quantifi ed as a z-score 
calculated on a single-case basis.
Results: The AD-related metabolic covariance pattern was calculated on the identifi cation cohort 
and was characterized by relatively decreased metabolic activity in the temporal and parietal 
regions and relatively increased metabolic activity in the subcortical white matter, cerebellum and 
sensorimotor cortex. Receiver-operating characteristic (ROC) curves were determined in cohort 
identifi cation cohort. At a cut-off  value of z=0.65, a sensitivity of 93% and a specifi city of 94% for 
correct AD classifi cation were determined.  In the confi rmation cohort, all the subjects with clinically 
probable AD diagnosis showed a high expression of the AD-related pattern whereas in all the 
subjects with a non-probable AD diagnosis a low expression was found. The mean Z-scores between 
probable and non-probable AD patients diff ered signifi cantly (Mann-Whitney U-test, p<0.000) and 
correlated signifi cantly with neuropsychological tests. 
Conclusion: The Alzheimer’s disease-related cerebral glucose metabolic covariance pattern 
identifi ed by SSM/PCA analysis was highly sensitive and specifi c for Alzheimer’s disease. This method 
is expected to be helpful in the early diagnosis of Alzheimer’s disease in clinical practice.
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6.1 INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative brain disease accounting for 50-60% of 
cases of dementia. AD is characterized by a severe decline in episodic memory together with general 
cognitive symptoms such as impaired judgement, decision making and orientation (McKhann et al. 
1984).  Other types of dementia are dementia with Lewy Bodies (DLB) and frontotemporal dementia 
(FTD) which together account for 15-25% of dementia cases (Gauthier et al. 2006). A correct clinical 
diagnosis may be diffi  cult, especially in early disease stages or in patients with for example comorbid 
depression, higher education or younger age (Bohnen et al. 2012). 
[18F]fl uorodeoxyglucose (FDG) PET imaging of the brain can be used to assist in the diff erential 
diagnosis of dementia (Bohnen et al. 2012). In AD, a decline of FDG uptake in posterior cingulate, 
temporoparietal and prefrontal association cortex - representing a reduction of the fi rst step of the 
glycolysis and thus the energy consumption in those brain regions - has been related to dementia 
severity (Herholz et al. 2002). Foster used visual interpretation of FDG-PET scans and statistical maps 
of patients with AD and FTD (Foster, et al. 2007). They showed that visual interpretation of regional 
brain glucose consumption is more reliable and accurate in distinguishing FTD from AD than clinical 
methods alone. Minoshima examined brain glucose metabolism of autopsy proven dementia with 
Lewy Bodies (DLB) and AD using an automated three-dimensional stereotactic surface projection 
technique (Minoshima et al. 2001). A signifi cant metabolic reduction in the occipital cortex, 
including the primary visual cortex, in patients suff ering from DLB compared to AD was found. We 
performed a retrospective study (Teune et al. 2010) selecting typical patients with parkinsonian and 
dementia syndromes, including AD, who had an FDG-PET scan at an early disease stage and a clear 
clinical diagnosis at follow-up.  Disease-specifi c regional cerebral diff erences in FDG uptake were 
found in all seven studied diseases using univariate voxel-based statistical parametric mapping 
(SPM) analyses comparing patient groups and healthy volunteers. In AD patients, most prominent 
decreases in metabolic activity were found in the angular gyrus and other parieto-temporal regions 
including precuneus extending to the posterior- and middle cingulate gyrus. 
Multivariate techniques like the scaled subprofi le model/principal component analysis (SSM/
PCA) are able to show information about underlying relationships between brain regions that are 
not captured by univariate techniques like SPM (Eidelberg. 2009, Habeck et al. 2008). In parkinsonian 
syndromes, SSM/PCA is increasingly used to study pathophysiological mechanisms and to assist in 
the diff erential diagnosis (Eckert et al. 2008, Ma et al. 2007a, Poston et al. 2012, Tang et al. 2010b, 
Teune et al. 2013). Huang used the SSM/PCA approach to identify specifi c spatial covariance 
patterns related to cognitive function in non-demented PD patients in addition to the previously 
found motor-related covariance pattern (Huang et al. 2007b).
However, almost no multivariate SSM/PCA techniques in patients with dementia, including 
Alzheimer’s disease, have been applied. 
The fi rst study that tried to apply this technique in patients with AD was presented by Scarmeas 
by using radiolabelled water (H2
15O)-PET scans to measure brain perfusion (Scarmeas et al. 2004). 
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They found sensitivities between 76-94% and specifi cities between 63-81% with considerable 
overlap in pattern expression among AD patients and controls. Therefore they concluded that the 
derived perfusion pattern cannot be used as a suffi  cient diagnostic test in clinical settings. Habeck 
performed univariate and multivariate discriminant analysis of brain FDG-PET scans to evaluate 
their ability to identify AD (Habeck, et al. 2008). They concluded that multivariate measures of AD 
utilize the covariance structure of imaging data and provide complementary, clinically relevant 
information that may be superior to univariate measures (Habeck, et al. 2008). In a parallel study by 
the same research group an AD-related spatial covariance pattern was identifi ed using continuous 
arterial spin labelling (CASL-MRI) (Asllani et al. 2008). However, they pointed out that it was necessary 
to do further research regarding specifi city and stability of the covariance patterns, before it can be 
used in clinical practice.
In this study we present and validate the Alzheimer’s disease-related glucose metabolic brain 
pattern using the SSM/PCA analysis identifi ed in a cohort of AD patients with a clinical diagnosis 
according to the the clinical research criteria for AD (McKhann et al. 1984) and scanned at an 
early disease stage. Furthermore, we tested this AD-related metabolic brain pattern prospectively 
in a second confi rmation cohort of patients with memory complaints ranging from subjective 





To identify AD-related metabolic brain patterns, we used data from a sample that was included in a 
previous study (Teune et al. 2010). This sample comprised 18 healthy controls and 15 patients with 
a diagnosis of AD according to the NINCDS-ADRDA clinical criteria (McKhann et al. 1984). The mean 
age of the 15 included AD patients was 65±10 years (mean±SD) and disease duration at the time of 
the FDG-PET scan 3±2 years. The diagnosis was confi rmed during a follow-up time after scanning 
of 3±2 years. These 15 AD patients and 18 healthy controls were used to identify an AD-related 
metabolic brain pattern.
Confi rmation cohort
The AD-related metabolic brain pattern that was identifi ed in the identifi cation cohort was 
prospectively tested in an independent confi rmation cohort. Inclusion criteria for the individual 
patients in the confi rmation cohort were a referral to the UMCG Center for Geriatric Medicine 
with a complaint of memory loss, a formal neuropsychological examination, and a FDG-PET scan. 
All patients gave written informed consent. In total 15 patients could be included in the present 
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analysis. Of these 15 patients, 9 patients (age 71±5; DD 3±1) were diagnosed as having probable 
AD according to the clinical research criteria for AD (McKhann, et al. 1984) by two independent 
dementia specialists (GI and JV), who were blinded to the outcome of the FDG-PET scan. Six patients 
were classifi ed as non-probable AD (age 63±11; DD 3±2) (one possible AD, two MCI and three 
subjective complaints).
6.2.2 Neuropsychological examination
Patients in the confi rmation cohort suspected having dementia received an extensive 
neuropsychological examination, covering several cognitive domains, including Mini Mental State 
Examination (MMSE) (Folstein et al. 1975); Dutch version: Kok & Verhey, 2002), for general cognitive 
function and orientation. Verbal memory (immediate recall, delayed recall, and recognition) was 
assessed with the Dutch version of the Rey Verbal Learning Test (RAVLT) (Saan and Deelman. 1986). 
Visual memory function (recall of cue- and association cards) was assessed with Visual Association 
Test (Lindeboom et al. 2002). Furthermore, attention and processing speed was assessed with the 
Stroop Colour Word Task (Stroop. 1935) and Trailmaking Test A & B (Reitan R. 1958). Language was 
assessed by naming and category fl uency; and visuospatial function and construction with the 
Clock Drawing and Visual Object and Space Perception (VOSP, subtests Incomplete Letters and Dot 
Counting) (Warrington and James 1991). Executive function was assessed with the Dutch version 
of the Frontal Assessment Battery (FAB) (Dubois et al. 2000) the Trailmaking Test part B and the Key 
Search task of the Behavioral Assessment of the Dysexecutive Syndrome (BADS) (Wilson et al. 1996)
6.2.3 FDG-PET scan acquisition
Patients were scanned 30 minutes after injection of approximately 200 MBq FDG in 4ml saline using a 
Siemens ECAT HR+ PET scanner or for some patients in the confi rmation cohort, a Siemens Biograph 
mCT camera in a 3D mode under standard resting conditions with the eyes closed. All reconstructed 
FDG-PET images were spatially normalized using the PET template supplied in SPM8 and smoothed 
with a 10 mm full-width at half-maximum (FWHM) isotropic Gaussian kernel in the identifi cation 
cohort and 12 mm for the individual patients in the confi rmation cohort. (SPM8; Functional Imaging 
Laboratory, running in Matlab 7.10.0 (R2010a, Mathworks))
6.2.4 FDG-PET statistical analysis
Identifi cation cohort
SSM/PCA was applied using software written in-house, based on the methods of Spetsieris and 
Eidelberg (Eidelberg. 2009, Spetsieris and Eidelberg. 2010). A 35% threshold of the whole-brain 
intensity maximum was applied to remove out-of-brain voxels which results in a mask of mainly 
grey matter, followed by a log transformation. After removing between-subject and between-
region averages, a principal component analysis (PCA) was applied. All components that together 
62
CHAPTER 6
described at least 50% of the variance were used for further analysis. A disease-related metabolic 
covariance pattern was determined by a linear combination of the selected principal components 
with the lowest AIC (Akaike information criterion) value (Akaike. 1974) in a stepwise regression 
procedure. Thereafter, a leave-one-out cross validation procedure was performed,  resulting in 
subject scores independent from the pattern identifi cation step and providing an estimate of the 
disease-related metabolic brain patterns and their variances. By dividing the estimate by its variance 
a T-score was obtained. Resulting patterns were thresholded at T > 3.7 (corresponding to p<0.001, 
assuming normality of the data) and overlaid onto a T1 MR template using MRIcron. 
Subject scores were transformed into z-scores with respect to the healthy control population and 
displayed, for each comparison separately, in a scatter plot. Receiving-operating-characteristic 
(ROC) curves were determined for the probability values of AD. Optimum cut-off  probability 
values for classifying individual patients were calculated by identifying an infl ection point on 
each ROC curve that corresponded to the best combination of sensitivity and specifi city. Patients 
were classifi ed as correctly diagnosed if their probability value was higher than the cut-off  value. 
Thereafter, we calculated sensitivity, specifi city, and positive and negative predictive value (PPV and 
NPV respectively). 
Confi rmation cohort
For each of the fi fteen individual patients, individual subject-scores were obtained for the expression 
of the AD-related metabolic brain pattern defi ned using cohort 1. These subject scores were 
transformed into z-scores with respect to the healthy control population and displayed separately 
for the probable and non-probable AD,  in a scatter plot. 
6.3 RESULTS
AD-related metabolic brain pattern calculated using the identifi cation cohort 
The fi rst four principal components accounted for 55% of the explained variance. In a stepwise 
regression model the lowest AIC value was calculated. The model with the lowest AIC value and 
hereafter considered as disease-related was determined by principal components 1 and 3 (36%). 
This AD-related covariance pattern was characterized by bilateral relatively decreased metabolic 
activity in the bilateral temporal regions, precuneus, posterior cingulate and angular gyrus, the 
inferior parietal region and supramarginalis. Relatively increased metabolic activity was seen in the 
subcortical white matter, cerebellum and sensorimotor cortex. (See fi gure 1 a) Their corresponding 
z-scores showed an overlap between the patients and healthy controls using the AD-related 
metabolic pattern. A cut-off  value of z=0.65 resulted in a sensitivity and positive predictive value 
of 93% and specifi city and negative predictive value of 94% for correct AD classifi cation of an 
individual patient. (See fi gure 1 b)
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AD-related pattern expression in the confi rmation cohort.
The Z-scores of the fi fteen individual subjects representing the AD-related pattern expression 
are displayed in fi gure 2. Table 1 displays correlations with the AD pattern Z-score and the 
neuropsychological profi les.
Figure 1:
a) A (T) map of the AD-related metabolic brain pattern using cohort 1 was overlaid on a T1 MR template. 
Relative metabolic decreases (blue) and increases (red) compared to the control group are thresholded at 
T= 3.7-6.7 (P< 0.001). Seven transversal slices through the brain are shown. 
b) Scatter plot and ROC curves for the AD-related metabolic brain pattern. On the Y-axis the leave-one-out 
z-scores are displayed and on the X-axis the group comparison of health controls vs AD. Receiving-operat-
ing-characteristic (ROC) curves were plotted for each comparison separately. * = infl ection point (z-score); 
Y-axis= sensitivity, X-axis= 1-specifi city; PPV = positive predictive value; NPV = negative predictive value. 
Figure 2:  Scatter plot of the individual patients with probable AD and non-probable AD of cohort 2 is dis-
played. On the Y-axis the leave-one-out z-scores are displayed and on the X-axis the individual patients with 
probable AD and non-probable AD. 
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MMSE and RAVLT immediate- and delayed recall showed signifi cant negative correlations with AD 
pattern scores, suggesting that subjects with a low score on memory tasks had a higher Z-score for 
the AD-related metabolic brain pattern. In the attention and information processing speed domain, 
Stroop Color/Word interference task and Trailmaking Test part A & B, signifi cant positive correlations 
with AD pattern expression were shown. High scores on the tasks for attention and speed refl ect a 
worse performance. 
Moderate to high, however non-signifi cant, correlations (negative and positive) were found 
between AD pattern expressions and Visual Association Test, Category Fluency, Clock Drawing, 
Stroop Color naming, and Frontal Assessment Battery.  
Diff erences in pattern expression between the 9 probable AD patients and the 6 non-probable 
AD patients were assessed using the Mann-Whitney U-test.  Mean of the Z-score of the probable 
AD-group was 1.6 and of the non-probable group 0.11 (p<0.000).
6.4 DISCUSSION 
The Alzheimer disease-related metabolic brain pattern presented in this study and obtained using 
FDG-PET scans and SSM/PCA analysis showed high sensitivity and specifi city. 
We have shown that individual patients within the independent confi rmation cohort with a 
diagnosis of non-probable AD (minimal or mild cognitive impairment) had a low Z-score for the AD-
related metabolic brain pattern and patients with a diagnosis of probable AD had a high Z-score for 
the AD-related pattern. Moreover, there was no overlap in z-scores between the individual subjects 
with probable AD and subjects with non-probable AD. 
Sensitivity and specifi city of the identifi ed metabolic brain pattern is higher in our study 
compared to the study of Scarmeas et al. This is possibly related to the lower signal-to-noise ratio of 
the  H2
15O-PET scans in their study. As Scarmeas suggested already in 2004, the fact that expression 
of the identifi ed pattern correlated with functional and cognitive measures in a population whose 
PET data were not used to derive the pattern, provides strong evidence for its validity (Scarmeas et 
al. 2004). This has now been confi rmed by our study presented here.
Moreover, sensitivity and specifi city are comparable to those found in larger studies including 
neuropathological confi rmation (Bohnen et al. 2012). These authors concluded that even in the 
situations in which FDG-PET disagreed with the clinical diagnosis, the correct pathological diagnosis 
was more likely to be congruent with FDG-PET than with the initial clinical diagnosis. 
The brain regions we found using the SSM/PCA analysis are comparable to the regions we 
already identifi ed using a univariate analysis in AD patients (Teune et al. 2010). The benefi t of 
the current approach is the ability to provide information about the way that brain areas co-vary 
with each other and to yield per subject a quantifi able expression (a Z-score) of the AD-related 
pathological pattern of neuronal degeneration. These Z-scores also correlated signifi cantly with 
several neuropsychological tests. Signifi cant negative correlations were found between the 
pattern and two memory subtests (RAVLT immediate and delayed recall) while signifi cant positive 
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correlations were found between two tasks for attention and processing speed and the pattern. Low 
scores on memory tests and high scores on attention and speed tasks refl ect a worse performance. 
This indicates that patients who performed worse on cognitive tests had a higher Z-score for the 
AD-related glucose metabolic brain pattern which in turn refl ects a glucose metabolism distribution 
pattern in the brain similar to  Alzheimer’s disease pathological patterns. 
After being taken up by the brain, glucose or its radiotracer analogue [18F]fl uoro-deoxyglucose, 
are phosphorylated by hexokinase to glucose-6-PO4 or fl uorodeoxyglucose-6-PO4, the fi rst step of 
the glycolytic process. However, FDG being a deoxy variant of glucose is not a substrate for further 
metabolism and consequently trapped in brain tissue for the duration of the scanning procedure. 
Thus the outcome measure of regional cerebral FDG-uptake measured by PET is the fi rst step of 
the glycolysis. From the early days on FDG has remained the only available radiotracer to detect 
accurately and reliably the cerebral glucose metabolism (Reivich, et al. 1979). As glucose is the only 
source of energy for the brain in normal conditions it refl ects the energy needs of underlying brain 
neuronal systems. The detected disease-related altered metabolic brain patterns using FDG-PET is 
therefore refl ecting the underlying pathological alterations of the aff ected brain regions. Since a 
few years FDG is commercially available and being used in many Nuclear Medicine Departments 
worldwide. Until recently the here presented statistical analysis techniques were not available for 
use in clinical practice, but can now be applied at a large scale.
Quantifying the magnitude of the expression of an AD-related metabolic covariance pattern 
on a single case basis may thus aid in the diff erential diagnosis of dementia. However, apart from 
confi rming the diagnosis of AD in an individual patient it will also be necessary to determine the 
abnormal brain patterns in other dementing conditions such as in frontotemporal dementia or 
dementia with Lewy Bodies in order to make the diff erential diagnosis of dementia more powerful. 
It will be clear that further elaboration of dementia patterns largely depend on the correct selection 
of the needed reference patient groups for the identifi cation procedure.
6.5 CONCLUSION 
The Alzheimer’s disease-related cerebral glucose metabolic covariance pattern identifi ed by SSM/
PCA analysis was highly sensitive and specifi c for Alzheimer’s disease. Individual patients within the 
confi rmation cohort with a diagnosis of probable AD had a high Z-score for the AD-related metabolic 
brain pattern, whereas patients with a diagnosis of non-probable AD had a low Z-score for the AD-
related metabolic brain pattern. This method is expected to be helpful in the early diagnosis of 
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In this chapter we present the prospective Dutch multicenter imaging project GLucose IMaging in 
ParkinsonismS (GLIMPS). 
It involves the establishment of a database of FDG-PET scans that depicts the glucose consumption 
of the brain in patients with neurodegenerative brain diseases. 
The project aims at testing the feasibility of a novel image-based classifi cation algorithm for the 
accurate and early individual diagnosis of patients with neurodegenerative brain diseases. 
7.1 FDG-PET IMAGING IN CLINICAL PRACTICE
[18F]-fl uoro-deoxyglucose positron emission tomography (FDG-PET) imaging is an easy and 
stable radiotracer method validated extensively through the years. FDG is only in recent years 
commercially available and being used in all the larger Nuclear Medicine Departments worldwide. 
FDG has remained the only available radiotracer to detect accurately and reliably the cerebral 
glucose metabolism. As glucose is the only source of energy for the brain it refl ects the energy needs 
of underlying brain neuronal systems. After being taken up by the brain, glucose or its radiotracer 
analogue FDG, are phosphorylated by hexokinase to glucose-6-PO4 or fl uorodeoxyglucose-6-
PO4, the fi rst step of the glycolytic process. However, FDG being a deoxy variant of glucose, is not 
a substrate for further metabolism and consequently trapped in brain tissue for the duration of 
the scanning procedure. Thus the outcome measure of regional cerebral FDG-uptake measured by 
FDG-PET is the fi rst step of the glycolysis. The detected disease-specifi c metabolic brain patterns 
using FDG-PET are therefore refl ecting the underlying pathological alterations of the aff ected brain 
regions. Specifi c brain regions degenerate and diff erent patterns of altered glucose metabolic brain 
activity develop in various neurodegenerative brain diseases (box 1). 
7.2 FDG-PET IMAGE ANALYSIS TECHNIQUES
At an early disease stage, visual interpretation of FDG-PET images can be diffi  cult, even for 
experienced specialists. As already mentioned in the previous chapters, measurement of glucose 
consumption with FDG-PET imaging allows us to identify disease-specifi c cerebral metabolic brain 
patterns in several neurodegenerative brain diseases at  an early disease stage, using the multivariate 
statistical analysis technique, called, Scaled Subprofi le modelling/ principal component analysis 
(SSM/PCA).
An important question is whether an early diagnosis of neurodegenerative brain disease in one 
individual is possible when individual metabolic patterns are compared with a database of disease-
specifi c metabolic brain patterns. It is possible to calculate a subject score by multiplying every 
voxel value in a subject scan by the corresponding voxel weight in the disease-related metabolic 
covariance pattern, with a subsequent summation over the whole brain volume. The obtained 
subject score indicates to what extent that patient expresses the disease-related pattern. In this way 
we can  prospectively calculate subject scores of an individual patient for to date identifi ed PD, MSA, 
PSP and AD disease-specifi c metabolic brain patterns. See box 2 for  examples of 2 patient cases. 
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7.3 GLIMPS DESIGN AND GOAL
The GLIMPS project  has been initiated  to create a national database of FDG-PET images of patients 
in diff erent disease categories together with their specifi c clinical information. 
Starting-point of the project must be the practical clinical situation of a patients who is suspected 
of having a neurodegenerative brain diseases and in whom the physician has a clinical reason to 
perform an FDG-PET scan. The FDG-PET scan must be considered as a useful diagnostic tool for 
Box 1
Healthy control: 
High symmetrical FDG uptake in the cortex, 
cerebellum, striatum and thalamus. Low 
FDG uptake  in the white matter/ventricles). 
Parkinson’s Disease (PD): 
Normal pattern or  high FDG uptake  in 
the striatum  compared to the cortex can 
be seen. 
Multiple System Atrophy (MSA): 
Low FDG uptake in the putamen and 
cerebellum.
 
Progressive Supranuclear Palsy (PSP): 
Low FDG uptake in the mediofrontal cortex. 
Sometimes low FDG uptake in the caudate 
nucleus.
Corticobasal degeneration (CBD): 
Asymmetrical low FDG uptake (contralateral 
to the most aff ected body side) in the cortex 
and in the striatum and thalamus. Cerebellar 
diaschisis: low FDG uptake in the cerebellum 
contralateral to the aff ected hemisphere.
 
Dementia with Lewy Bodies (DLB): 
Low FDG uptake in the occipital regions, 
especially visual cortex. Sometimes low 
FDG uptake parietal cortex.
Alzheimer’s Disease (AD): 
Low FDG uptake in the parietal cortex 
and posterior cingulate. Low FDG uptake 
in temporal and frontal regions (in more 
advanced stages).
Frontotemporal Dementia (FTD): 
Low FDG uptake (sometimes asymmetrical 
in the lateral frontal, mediofrontal and 
temporal cortex)
B. Typical example of FDG-PET  imaging of individual patients
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doctor and patient to determine the global and regional glucose consumption in the brain.
The fi rst goal of the project is the benefi t in clinical practice by assisting in the diff erential 
diagnosis of neurodegenerative brain diseases in individual patients. The possible presence of a 
disease-specifi c metabolic brain pattern in an individual patient will be calculated by applying 
the image-based classifi cation algorithm for the to date identifi ed metabolic brain patterns. The 
outcome of the classifi cation algorithm will be compared to the fi nal clinical diagnosis to evaluate 
the eff ectiveness of the proposed new technique. A second goal is to develop further the glucose 
metabolic brain patterns in diff erent disease categories in specifi c scientifi c projects. It will be 
clear that further elaboration of glucose metabolic brain patterns for neurodegenerative brain 
diseases largely depend on the correct selection of the necessary reference patient groups for the 
identifi cation procedure.
Expanding the sample size will also increase sensitivity and specifi city of the listed metabolic 
brain patterns and will enable subclassifi cations in for example left/right body-side aff ected patients. 
Furthermore, a large control sample consisting of enough patients within diff erent age categories 
is important to study diff erences in for example man and women, right left handedness and to see 
diff erences in brain patterns in an aging population. In this way, patient care focused on the early 
diff erential diagnosis of patients with neurodegenerative brain diseases is expected to improve. 
7.4 GLIMPS ORGANISATION
This project has been initiated by the Department of Neurology of the University Medical Center 
Groningen (UMCG) and is coordinated in close collaboration with the Department of Nuclear 
Medicine and Molecular Imaging (NGMB) in the UMCG, Neuro Imaging Center (NIC) and the Johann 
 Bernoulli Institute for Mathematics and Computer Science (Scientifi c Visualisation and Computer 
Graphics group) at the RUG. Expertise center TARGET is involved to develop and maintain the 
GLIMPS database. Researchers and physicians of these departments together form the GLIMPS 
project group (see our website www.glimpsproject.com)
7.4.1 Department of Neurology
GLIMPS forms part of the main longstanding research topics of the department of Neurology at the 
UMCG i.e. clinical and pathophysiological studies of movement disorders in particular Parkinson’s 
disease within the context of Molecular Mechanisms of Neurodegeneration. The department 
is playing an important role in the development of the protocol. It includes the information for 
patients, clinical parameters which need to be collected, clinical research criteria and the latest 
version of the image acquistion and scanning protocols. Selection of patients takes place at the 
outpatient Neurology department. Inclusion criteria for the GLIMPS project are patients who are 
suspected of having a neurodegenerative brain disease and in whom the physician has a clinical 
reason to perform an FDG-PET scan. These patients can be asked to participate in the GLIMPS 
project. After informed consent, clinical and scan information can be stored anonymously in the 
GLIMPS database.  
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7.4.2 Department of Nuclear Medicine and Molecular Imaging
The Department of Nuclear Medicine and Molecular Imaging at the UMCG provides daily performance 
of brain PET scans using radiotracers for common clinical use, like FDG ([F-18]fl uoro-deoxy-glucose) 
and FDOPA ([F-18]fl uoroDOPA), but also a range of experimental tracers. The department plays an 
important role in the GLIMPS project concerning image acquistion and reconstruction of the scans 
performed at the UMCG. Apart from that they have developed the GLIMPS image acquistion and 
scanning protocols in order to ensure that scans of diff erent centers can be compared with each 
other.
7.4.3 NeuroImaging Center (NIC)
The NIC is a joint venture of the University Medical Center Groningen (UMCG) and theUniversity 
of Groningen (RUG). Currently, it is equipped with a 3 Tesla MR-scanner, EEG and TMS equipment 
and data analysis facilities. Research is focused on using and improving neuroimaging techniques 
for behavioral and cognitive neurosciences. The NIC supervises the running of the image-based 
algorithms and further improves their performance as an image-analysis tool.
7.4.4 Scientifi c Visualisation and Computer Graphics
The Scientifi c Visualisation and Computer Graphics (SVCG) research group, within the Department 
of Computer Science, is part of the Johann Bernoulli Institute of Mathematics and Computer Science 
(JBI) of the University of Groningen, the Netherlands. 
The group carries out research in the area of scientifi c visualization, information visualization, 
software visualization, multiscale shape analysis, illustrative computer graphics, and innovative 
interfaces using large displays. SVCG is participating in implementing the new versions of pattern 
recognition methods in the GLIMPS projects to be developed beyond the currently available image 
covariance techniques (Scaled Subprofi le Model, SSM).
7.4.5 TARGET
The Donald Smits Center for Information Technology at the RUG, the Faculty of Mathematics and 
Natural Sciences together with the UMCG and other Institutions and companies have created 
the expertise center TARGET. Expertise center Target is building a sustainable economic cluster of 
intelligent sensor network information systems in the Northern part of the Netherlands, aimed at 
data management for very large amounts of data. 
Target’s role in GLIMPS is to develop and maintain the GLIMPS database, which will be hosted on 
the Target testbed, according to the functionality requirements of the project. All anonymous data 
is electronically transferred to the GLIMPS database.  Target is also involved in ensuring smooth 
and reliable implementation of the image-based classifi cation algorithm on its processing cluster 
facilities. In the end, the diagnosis based on the image-based classifi cation algorithm will be 
compared to the clinical diagnosis to evaluate the eff ectiveness of the proposed new technique.  
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7.4.6. Other participating centers
Collaboration with other Dutch medical centers involved in our project will broaden our patient 
base and enable us to test the feasibility of this  approach across diff erent movement disorder clinics 
and imaging centers. At the moment more than 10 centers in the Netherlands are participating. It 
is the intention that the database and the classifi cation model is developed in such a way that it 
should be useful in clinical practice for each participating center. Furthermore, scientifi c questions 
can be formulated by each participating center.
Internationally an important and intensive collaboration exists with the Feinstein group (Center 
for Neurosciences, from the Feinstein Institute for Medical Research, Manhasset, New York). This 
collaboration is most relevant since that group has many years of experience with the SSM/PCA 
method and provided the proof of principle of the method to be applied here. The Feinstein group 
will serve as international reference partner for our project.  
7.5 GLIMPS in clinical practice 
Clinical information and FDG-PET scan data will be electronically transferred in a secure and 
confi dential manner to the GLIMPS database at TARGET of the RUG, where the image-based 
classifi cation algorithm will be performed. Individual physicians of the departments of Neurology, 
geriatrics or nuclear medicine of each participating center will each receive a username and 
password which they can use to access the GLIMPS database. Each participating center has its own 
center number under which all patients of that center can be uploaded. Before patient information 
can be stored in the database, patients have to be informed about the purpose of the project and 
they have to sign informed consent for the anonymous storage of their patient data. After informed 
consent, clinical and scan information can be uploaded to the GLIMPS database. Before a referring 
physician can enter a new patient, he will receive a GLIMPS number which belongs to that patient. 
This number will need to be stored together with the medical chart of the patient, in order to inform 
the referring physician which patient belongs to which number. In this way the referring physician 
can access the own patient population so that necessary additions or repeated studies can be 
added. The data of patients of the other centers are not accessible. After complete upload of all 
necessary data, the image-based classifi cation algorithm will be applied by the researchers of the 
GLIMPS project and feedback will be given within two weeks. This feedback will consist of z-scores 
of each of the known disease-related metabolic brain patterns (currently PD, MSA, PSP and AD, for 
an example of the feedback see box 2). 
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Under normal conditions, the spatial distribution of resting cerebral blood fl ow and cerebral 
metabolic rate of glucose are closely related. A relatively new magnetic resonance (MR) 
technique, pseudo-continuous arterial spin labeling (PCASL), was used to measure regional brain 
perfusion. Fourteen Parkinson’s disease patients and seventeen healthy controls underwent [18F]-
fl uorodeoxyglucose  positron emission tomography (FDG-PET) imaging and PCASL-MRI to assess 
(dis)similarities between perfusion and glucose metabolism. Data were analyzed using scaled 
subprofi le model/principal component analysis (SSM/PCA).
Unique Parkinson’s disease-related perfusion and metabolic covariance patterns were identifi ed, 
indicating that both methods contribute to the diagnosis of individual parkinsonian patients.
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8.1 INTRODUCTION
For many years, nuclear imaging techniques have been used to visualize disease-related changes in 
brain perfusion and glucose metabolism in neurodegenerative brain diseases. 
Sokoloff  et al. were the fi rst to report that under physiological steady state conditions, cerebral 
blood fl ow (CBF) is coupled to the level of cerebral oxygen (CMRO2) and glucose consumption 
(Sokoloff . 1977). Leenders et al measured rCBF and rCMRO2 in patients with Parkinson’s disease (PD). 
They showed an increase of regional blood fl ow and oxygen metabolism in the basal ganglia of the 
aff ected hemisphere in PD patients with predominantly unilateral disease (Leenders et al. 1984a). In 
the 1980’s, a SPECT tracer, 99Tcm-hexamethylpropyleneamine oxime (99Tcm-HM-PAO), was developed 
to detect cerebral blood fl ow with SPECT-imaging. The PET tracer [18F]-fl uorodeoxyglucose (FDG) 
allows the measurement of cerebral metabolic rate of glucose (CMRglc). Regional diff erences in 
cerebral glucose metabolism have been reported in parkinsonian syndromes using univariate 
methods (Teune et al. 2010). Data-driven multivariate methods are increasingly used to examine 
disease-specifi c metabolic covariance patterns in parkinsonian syndromes (Ma et al. 2007a). This 
has improved our understanding of the pathophysiology of these diseases as well as our ability to 
diagnose patients at an earlier disease stage (Tang et al. 2010a, Teune et al. 2013). Ma reproduced 
this PD-related metabolic covariance pattern, using H2
15O PET scanning,  indeed suggesting that 
cerebral blood fl ow and glucose metabolism are tightly coupled in PD patients (Ma et al. 2007a). 
However, in clinical practice, blood fl ow measurements with PET are not widely used because it 
is a demanding and time-consuming procedure, while spatial resolution of SPECT is less optimal. 
Recently, it has become possible to measure brain perfusion with a relatively new MR technique, 
pseudo-continuous Arterial Spin Labeling (PCASL). It permits the noninvasive measurement of 
perfusion with MRI by using a train of radio frequency (RF) pulses and magnetic fi eld gradient 
pulses to achieve labeling of spins in fl owing blood (Dai et al. 2008, van Osch et al. 2009). Ma et al 
analyzed the expression of the existing PD- related metabolic covariance pattern in a small number 
of parkinsonian patients using perfusion MRI (continuous arterial spin labeling) and concluded that 
perfusion MRI can be used for accurate quantifi cation of disease-related covariance patterns (Ma et 
al. 2010a). Melzer et al were the fi rst to identify a PD-related perfusion covariance pattern (Melzer 
et al. 2011). In this study we identifi ed a PD-related perfusion and metabolic covariance pattern in 
the same patients using PCASL and FDG-PET imaging and assessed (dis)similarities in the disease-
related pattern between perfusion and metabolism in PD patients. 
8.2 PATIENTS & METHODS
8.2.1 Subjects
The study was approved by the medical ethics committee of the University Medical Center 
Groningen. Voluntary written informed consent was obtained from each subject after verbal and 
written explanation of the study, in accordance with the declaration of Helsinki. This study is part 
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of a larger study: in this part 14 PD patients (4 female, 10 male; mean age 63.8 years) and 17 gender 
and age-matched healthy controls (HC) (5 female, 12 male; mean age 61.5 years) participated. PD 
patients had to fulfi ll the UK brain Bank criteria for PD (Litvan et al. 2003). Healthy controls were 
not allowed to have fi rst-degree family members with parkinsonism or dementia.  All subjects 
underwent MRI and within 8 weeks an FDG-PET scan and two neuropsychological tests (Mini Mental 
State Examination (MMSE) and Frontal Assessment Battery (FAB)) and PD patients underwent the 
Unifi ed Parkinson’s Disease Rating Scale (UPDRS) part 3: motor symptoms. Neuropsychological 
scores did not diff er between groups (mean HC: MMSE 29, FAB 17; mean PD: MMSE 28, FAB 16) 
indicating that PD patients were non-demented. PD patients had mild to moderate motor symptoms 
with Hoehn&Yahr stage: mean 1.3; standard deviation (SD) 0.5 and a UPDRS part 3: mean 18; SD 
7. Antiparkinsonian medication was withheld for at least 12 hours and benzodiazepines 24 hours 
before MRI and FDG-PET scanning.
8.2.2 Image acquisition and preprocessing
MR imaging was performed on a 3T MRI scanner (Achieva 3 Tesla, Philips healthcare, Best, The 
Netherlands) using a standard 8-channel SENSE head coil. Subjects were wearing ear protection 
and instructed to lie still with their eyes closed, and to avoid falling asleep.
To enable PCASL imaging, the scanner was equipped with locally developed software. Pseudo-
continuous labeling was performed by employing a train of Hanning-shaped RF pulses (tip angle 
18°, duration 0.5ms) with an interpulse pause of 0.5 ms in combination with a balanced gradient 
scheme. PCASL images were obtained in a dynamic mode of 2x30 volumes (labeled and control) 
with an echo time of 14 ms, repetition time (TR) of 4200 ms, 23 axial slices, fi eld of view (FOV) 
240 mm with an 80x80 matrix and an isotropic voxel size of 3x3x6 mm. All 30 labeled and control 
volumes were fi rst motion-corrected in SPM8 (Functional Imaging Laboratory, running in Matlab 
7.10.0 (R2010a, Mathworks)). Volumes were smoothed with an 8 mm full-width-at-half-maximum 
isotropic Gaussian kernel (FWHM). Analogue to van Dijk (Van Dijk, et al. 2010), volumes were 
fi ltered against a time-course extracted from a ROI in white matter and liquor in order to diminish 
physiological noise. Thereafter, labeled perfusion-weighted images were subtracted from control 
images, creating one mean PCASL image per subject. These steps were performed using Matlab 
scripts developed in-house. Normalization with respect to the global mean is intrinsic in the used 
statistical analysis method (see below). 
FDG-PET imaging was performed in a 3D mode using a Siemens Biograph mCT-64. Image 
acquisition was performed in a resting state with the subject’s eyes closed in a dimly lighted room 
with minimal auditory stimulation. A 6-minute static frame was acquired starting 30 minutes after 
the injection of 200 MBq FDG in 4ml saline. 
The FDG-PET images were iteratively reconstructed using the OSEM algorithm with 3 iterations and 
24 subsets on a matrix of 400x400 and smoothed with 5 mm FWHM. No zoom was applied, resulting 
in images with an isotropic voxel-size of 2 mm with a specifi ed resolution of 5 mm in the center of 
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the fi eld of view. Scatter and attenuation correction were applied based on the acquired low dose 
CT. 
A study-specifi c template of all mean PCASL images was spatially normalized to a standard brain PET 
template (Montreal Neurological Institute; MNI) using SPM8 and then used to spatially normalize 
the individual mean PCASL images. An example of the mean PCASL images of seventeen healthy 
controls is shown in Figure 1 a. FDG-PET images were directly spatially normalized to a PET template 
and then both were smoothed with 10 mm FWHM.
8.2.3 Statistical analysis
SSM/PCA was applied using software written in-house, based on methods of the Eidelberg 
research group (Spetsieris and Eidelberg. 2010). A 35% threshold of the whole-brain maximum was 
applied for FDG-PET images to remove out-of-brain voxels, which results in a mask of mainly grey 
matter, followed by a log transformation. This grey matter mask was then applied to the PCASL 
images without subsequent log transformation. After removing between-subject and between-
region averages, a principal component analysis (PCA) was applied. All components that together 
described at least 50% of the variance were used for further analysis. A disease-related metabolic 
covariance pattern was determined by a linear combination of the selected principal components 
with the lowest AIC (Akaike information criterion) value in a stepwise regression procedure. 
Thereafter, a leave-one-out cross validation procedure was performed, resulting in subject scores 
independent from the pattern identifi cation step. This provides an estimate of the disease-related 
metabolic brain patterns and their variances. By dividing the estimate by its variance a T-score was 
obtained. Resulting disease-specifi c metabolic and perfusion brain patterns were thresholded at 
T=2.5 (corresponding to p<0.02) and overlaid onto a T1 MR template using MRIcron. Subject scores 
for the PD-related metabolic and perfusion patterns were transformed into z-scores with respect to 
the healthy control population. Moreover, z-scores of the PCASL images were calculated using the 
glucose metabolic covariance pattern as a reference. A correlation analysis was performed between 
z-scores of the PCASL- and FDG images on the PD-related glucose metabolic brain pattern. 
8.3 RESULTS
The PD-related perfusion covariance pattern was characterized by relatively decreased cortical 
metabolic activity bilaterally in the temporal, insular, posterior parietal, inferior parietal, lateral 
occipital and prefrontal association cortex. Relative increases were seen in the cerebellum and pons, 
right thalamus and pallidum, sensorimotor cortex, paracentral lobule and supplementary motor 
area (SMA) (Figure1 b).
The PD-related metabolic covariance pattern was characterized by relatively decreased cortical 
metabolic activity in the temporal, posterior parietal, inferior parietal, lateral occipital, prefrontal 
association cortex and SMA. Relative increases were seen in the cerebellum and pons, thalamus and 
pallidum, sensorimotor cortex, limbic association cortex, paracentral lobule and left SMA (Figure1 b).
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Figure 1: A) Example of the mean PCASL images of all healthy controls. Seven transversal slices through the 
brain are shown. B)  (T) maps of the PD-related perfusion (upper row) and metabolic covariance brain patterns 
were overlaid on a T1 MR template. Relative perfusion and metabolic decreases (blue) and increases (red) com-
pared to the control group are thresholded at T= 2.5-5.0 (P< 0.02). Seven transversal slices through the brain are 
shown.
Figure 2: Correlation between the PD-related 
metabolic brain pattern expression measured 
with FDG and PCASL. On the X-axis the leave-
one-out z-scores are displayed from the PCASL 
scans. On the Y-axis the leave-one-out z-scores 
are displayed from the FDG-PET scans. Healthy 
controls are denoted by open triangles; PD pa-
tients by open circles.
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We computed the z-scores of FDG and PCASL images on the PD-related metabolic brain pattern and 
performed a correlation analysis. The Pearson correlation coeffi  cient was 0.498 (p<0.007) (Figure 2).
8.4 DISCUSSION
In this study we identifi ed PD-related perfusion and glucose metabolic brain patterns measured in 
the same patients. The PD-related metabolic covariance brain pattern is in high accordance with 
previously described disease-related metabolic brain patterns in diff erent cohorts in PD patients 
using standard clinical FDG-PET imaging (Ma et al. 2007a, Teune et al. 2013). Furthermore, we 
obtained a disease-specifi c perfusion brain pattern using PCASL-MR imaging. Our disease-related 
pattern is comparable to the PD-related perfusion brain pattern described by Melzer, characterized 
by decreased perfusion in posterior parieto-occipital cortex, middle frontal gyri and preserved 
perfusion in globus pallidus, putamen, anterior cingulate and post/precentral gyri with decreased 
perfusion activity in the posterior parieto-occipital cortex, posterior medial cortex and middle 
frontal gyrus and increased activity in bilateral globus pallidus, putamen en primary sensorimotor 
cortex and SMA (Melzer et al. 2011). The most characteristic diff erence between our perfusion brain 
pattern and previous reports (Fernández-Seara et al. 2012, Melzer et al. 2011), is the decrease of 
cerebral perfusion in the insular cortex on both sides in our data.  However, Helmich et al have 
shown that PD patients had decreased connectivity between the posterior putamen and various 
cortical regions contributing to the corticostriatal loop, including the insula using resting-state 
functional MRI data (Helmich et al. 2010). 
Performing PCASL and FDG-PET imaging in the same patients enabled a comparison between 
both patterns. Z-scores of  PCASL datasets onto the metabolic pattern correlated positively (0.498) 
with the z-scores of FDG datasets onto the metabolic pattern. This value indicates there is substantial 
overlap, however, not complete. As discussed above, the larger perfusion decrease in the PD-related 
pattern in cortical regions including the insula than in the metabolic brain pattern, is suggesting 
that PCASL, is indeed adding relevant information to the PD-related pattern. 
Another diff erence is the less pronounced increased perfusion in the basal ganglia in the 
perfusion-related pattern compared to the metabolic brain pattern. This is probably related to a 
lower signal-to-noise ratio. It is known that MRI head coils with multiple receive channels result in 
better signal to noise ratio in the cortex than in deeper brain structures. 
Our data shows that PCASL is a promising technique, which gives supplementary information to 
FDG-PET and could thus be used as an additional measurement to improve image-based diagnosis 
of parkinsonian syndromes.
8.5 Conclusion
We identifi ed PD-related perfusion and metabolic brain patterns using PCASL and FDG-PET in 
the same patients which were comparable with results of existing research. In this respect, PCASL 
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The main aim of this thesis was to investigate diff erences in glucose metabolism in various 
neurodegenerative brain diseases using [18F]-fl uorodeoxyglucose (FDG)-PET imaging. Furthermore, 
specifi c analysis techniques which can assist in the applicability of these brain patterns in clinical 
practice were investigated. In the following paragraphs specifi c fi ndings and results will be 
highlighted. In the second part of this chapter, possibilities to extend to other image modalities and 
new methods that are currently subject of further study will be discussed.
9.1 BRAIN IMAGING IN THE DIFFERENTIAL DIAGNOSIS OF PARKINSONIAN SYNDROMES 
The diff erential diagnosis of neurodegenerative brain diseases may be diffi  cult on clinical grounds 
only. Parkinson’s disease (PD) is the second most common neurodegenerative brain disease 
after Alzheimer’s disease (AD). PD is manifested clinically by bradykinesia, muscular rigidity 
and sometimes rest tremor. Supportive features of the diagnosis are a unilateral onset of motor 
symptoms, progressive disorder and a good and consistent levodopa response (Litvan, et al. 2003). 
Especially at early disease stages, it can be diffi  cult to distinguish PD from other neurodegenerative 
parkinsonian syndromes such as multiple system atrophy (MSA), progressive supranuclear palsy 
(PSP), corticobasal degeneration (CBD) or dementia with Lewy Bodies (DLB). In general neurological 
practice, diagnostic accuracy of parkinsonian syndromes is around 76% (Hughes, et al. 1992).  In 
chapter 2, radiotracer neuroimaging techniques using positron emission tomography (PET) or 
single photon emission computed tomography (SPECT) are discussed which can be helpful to 
diff erentiate PD from other diseases. Presynaptic dopaminergic imaging either with [18F]F-DOPA PET 
or [123I]FP-CIT SPECT is used to diff erentiate between patients with parkinsonian features associated 
with a presynaptic dopaminergic defi cit such as PD, (but also MSA, PSP, CBD and DLB) and without 
a presynaptic dopaminergic defi cit such as essential tremor, drug-induced parkinsonism or vascular 
parkinsonism. In a recent study of Hellwig (Hellwig, et al. 2012), the diagnostic accuracy of FDG-PET 
compared to [123I] iodobenzamide (IBZM) for SPECT imaging was investigated. They concluded that 
the diagnostic accuracy of FDG-PET for discriminating Lewy Body Dementia from other parkinsonian 
syndromes is considerably higher than for IBZM-SPECT. This suggests that FDG-PET should replace 
IBZM-SPECT in clinical routine examinations of parkinsonian patients. In order to diff erentiate 
within the group of before mentioned neurodegenerative parkinsonian syndromes, disease-related 
metabolic brain patterns identifi ed with FDG-PET imaging could be of great assistance in the 
individual clinical diagnosis (see below). 
9.2 FDG-PET IMAGING IN THE DIFFERENTIAL DIAGNOSIS OF NEURODEGENERATIVE BRAIN 
DISEASES 
FDG-PET imaging is increasingly available for routine clinical practice and has remained the 
only available radiotracer to detect accurately and reliably the cerebral glucose metabolism. 
As glucose is the only source of energy for the brain, it refl ects the energy needs of underlying 




FDG, are phosphorylated by hexokinase to glucose-6-PO4 or fl uorodeoxyglucose-6-PO4, the fi rst 
step of the glycolytic process. However, FDG being a deoxy variant of glucose, is not a substrate 
for further metabolism and consequently trapped in brain tissue for the duration of the scanning 
procedure. The outcome measure of regional cerebral FDG-uptake measured by PET is the fi rst 
step of the glycolysis. The detected specifi c metabolic brain patterns using FDG-PET are therefore 
refl ecting the underlying pathological alterations of the aff ected brain regions. Specifi c brain 
regions degenerate and diff erent patterns of altered glucose metabolic brain activity develop in 
various neurodegenerative brain diseases, before structural (atrophy) changes can be detected with 
imaging techniques.
9.2.1 Univariate analysis method 
In chapter 3, we have performed a retrospective study selecting typical patients with PD, MSA, PSP, 
CBD DLB, AD and frontotemporal dementia (FTD). At the time of referral for imaging, the clinical 
diagnosis of most patients was uncertain. The fi nal clinical diagnoses according to established 
clinical research criteria (Gilman et al. 2008, Litvan et al. 1996, Litvan et al. 2003, Mahapatra et al. 
2004, McKeith. 2006, McKhann et al. 1984, McKhann et al. 2001) were made after a follow up time 
after scanning of PD 4±3 (mean±SD in years), MSA (2±1), PSP  (3±2), CBD  (3±1), DLB (2±1), AD (3±2) 
and FTD (3±1). 
To identify diff erences between patients and controls we used a univariate voxel-based analysis 
technique called statistical parametric mapping (SPM). Images of each of the seven patient groups 
were separately compared to 18 healthy controls using this SPM procedure and a two-sample t-test. 
Disease-specifi c patterns of relatively decreased metabolic activity were found in PD (contralateral 
parieto-occipital and frontal regions), MSA (bilateral putamen and cerebellar hemispheres), PSP 
(prefrontal cortex and nucleus caudatus, thalamus and mesencephalon), CBD (contralateral cortical 
regions), DLB (occipital and parieto-temporal regions), AD (parieto-temporal regions), and FTD 
(fronto-temporal regions). In these patients, scanned at an early disease stage, typical diff erences 
between patient groups and healthy controls were found for each disease. In chapter 4, an 
overview of the literature of disease-specifi c metabolic brain patterns in several neurodegenerative 
brain diseases is given. Furthermore, advances of using multivariate analysis methods compared 
to univariate methods are outlined. In a multivariate statistical analysis technique, called Scaled 
Subprofi le Modelling/Principal Component Analysis (SSM/PCA), not only group diff erences between 
patients and controls can be identifi ed like in univariate methods, but it is also possible to identify 
relationships in relatively increased and decreased metabolic activity between diff erent brain 
regions in combined samples of patients and control scans (Eidelberg. 2009, Moeller, et al. 1987).
9.2.2 Multivariate analysis method
In chapter 5 we validated disease-related metabolic brain patterns for PD, MSA and PSP using 
SSM/PCA in the same patients and controls that were used in the univariate analysis of chapter 
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3. Validation showed that the disease-related metabolic brain patterns were highly similar to  the 
earlier described group diff erences in chapter 3 and discriminative of the three disorders. The 
fi ndings are consistent with previous studies. However, some interesting diff erences can be noted. 
In our study the PD-related metabolic covariance pattern was characterized by an asymmetrical 
relatively decreased metabolic activity, contralateral to the aff ected body side in 14 out of 20 
patients, comprising the (posterior) parietal association cortex, visual cortex, lateral premotor and 
prefrontal association cortex. To our knowledge, an asymmetrical PD pattern has not been described 
before (Huang et al. 2007c, Ma et al. 2007a). 
Moreover, Tang studied longitudinal changes in network activity in each cerebral hemisphere, 
focusing specifi cally on the “presymptomatic” hemisphere, ipsilateral to the initially involved body 
side, to see whether the network changes appear at or before symptom onset. In the context of PD, 
the cerebral hemisphere ipsilateral to the initially aff ected limbs can be considered “presymptomatic” 
at least until symptoms appear on the opposite body side. They found that elevations at the network 
level of the PD motor-related pattern (PDRP) were already present at baseline in both hemispheres. 
This contrasts with hemispheric expression of the PD cognition-related pattern 4 years after the 
appearance of the motor network abnormality which was characterized by decreased metabolic 
activity in the contralateral precuneus (Tang, et al. 2010a). This localized metabolic change may 
refl ect the earliest stages of early cognitive decline in Parkinson disease as defi ned by mild cognitive 
impairment (Huang, et al. 2007a). 
We included PD patients at an early disease stage even before the clinical diagnosis was clear. 
However we did not diff erentiate between PD specifi c motor and cognitive related changes and 
we have not studied this cohort over time. Nonetheless, we hypothesize that the appearance of 
cortical metabolic decreased activity contralateral to the most aff ected body side in our cohort 
could be an early marker of advancing disease including the development of  neuropsychological 
defi cits. Future studies should be carried out to predict onset and progression of specifi c PD-related 
symptoms. Further data inclusion will increase sensitivity and specifi city of the listed metabolic 
brain patterns. Application of this SSM/PCA method may also be useful for other parkinsonian and 
dementia syndromes to enhance diagnostic precision. 
We extended the SSM/PCA approach in chapter 6 to identify an Alzheimer’s Disease-related 
glucose metabolic brain pattern. Group diff erences in regional cerebral glucose utilisation of 
patients with dementia compared to healthy controls are well-known. However, multivariate 
analysis techniques aiming at identifying diagnostic neural networks in diseases, have been 
applied less frequently. The aim of this study was to present and validate an AD-related glucose 
metabolic brain pattern and to apply it prospectively in a second cohort of individual patients 
with memory complaints. The identifi cation cohort consisted of the same AD patients and controls 
already described in chapter 3. The AD-related glucose metabolic brain pattern was characterized 
by relatively decreased metabolic activity in the temporal and parietal regions and relatively 




The metabolic brain pattern we found using the SSM/PCA analysis was comparable to the regions 
we already identifi ed using a univariate analysis in AD patients (see chapter 3) with a sensitivity of 
93% and a specifi city of 94% for the AD-related metabolic brain pattern. Furthermore, we applied 
this method to investigate the ability of the identifi ed AD-related metabolic covariance pattern to 
discriminate between individual patients with probable AD and non-probable AD (possible AD, 
mild cognitive impairment (MCI) or subjective complaints) and the association of the metabolic 
patterns with neuropsychological tests. This part of the study was done in an independent cohort of 
15 patients referred to our memory clinic (confi rmation cohort). In the confi rmation cohort, all the 
subjects with clinically probable AD diagnosis showed a high expression of the AD-related metabolic 
brain pattern whereas in all the subjects with a non-probable AD diagnosis a low expression was 
found. 
9.3 FDG-PET IMAGING AND THE SSM/PCA METHOD IN CLINICAL PRACTICE
Since a few years FDG is commercially available and being used in many Nuclear Medicine 
Departments worldwide. Now we have the possibility, based on the disease-related patterns for PD, 
MSA, PSP and AD, to obtain a score for an individual subject. This score is calculated by multiplying 
every voxel value in a subject scan by the corresponding voxel weight in the disease-related 
metabolic covariance pattern, with a subsequent summation over the whole brain volume. The 
obtained subject score indicates to what extent that patient expresses the disease-related pattern. 
In chapter 5 we showed that the “simple” comparison between healthy controls and patient groups 
already yielded a high sensitivity and specifi city for correctly classifying PD, MSA or PSP patients. 
Tang et al have already demonstrated an image-based classifi cation routine with high specifi city 
to distinguish between PD and MSA/PSP and in a second step between MSA and PSP compared 
to controls. (Tang et al. 2010b). We performed another analysis in chapter 5 by directly comparing 
PD and MSA instead of a comparison against healthy controls and demonstrated that especially 
specifi city increased. This is relevant for applying this method in clinical practice because the clinical 
motivation for a FDG-PET originates from doubts between PD or MSA, not between healthy or PD. 
In a recent study of Hellwig (Hellwig, et al. 2012), the diagnostic accuracy of FDG-PET in discriminating 
parkinsonian patients was investigated. FDG-PET scans were analyzed by visual assessment 
including individual voxel based statistical maps (a 3D stereotactic surface projection technique 
(3D-SSP)). First, a diff erentiation between MSA, PSP and CBD from DLB was made, followed by a 
subclassifi cation in MSA, PSP and CBD. Sensitivity and specifi city of FDG-PET was 77/97% for MSA, 
74/95% for PSP and 75/92% for CBD respectively. These studies compared only two classes at a time 
or in two levels (healthy and patient group, or two patient groups). This puts forward a research 
challenge to improve the SSM/PCA method, to be able to distinguish diff erent neurodegenerative 
brain diseases from each other in one analysis. One might consider machine learning approaches 
like decision-tree methods to be able to compare more than two patient groups at the same time 
and possibly detect subclassifi cations within patient groups (see future perspectives).
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Rather than demonstrating pattern specifi city in group comparisons, it is important to know 
whether an early diagnosis of neurodegenerative brain disease of one individual is possible when 
individual metabolic patterns are compared with a database of disease-specifi c metabolic brain 
patterns. 
In chapter 7 we present the prospective Dutch multicenter imaging project GLucose IMaging 
in ParkinsonismS (GLIMPS) which aims at testing the feasibility of a novel image-based classifi cation 
algorithm for the accurate and early individual diagnosis of patients with neurodegenerative brain 
diseases. However, apart from confi rming the diagnosis of a neurodegenerative brain disease in 
an individual patient, it will also be necessary to determine abnormal glucose metabolic brain 
patterns in other parkinsonian and dementia syndromes such as in CBD, DLB and FTD in order 
to make the diff erential diagnosis of dementia more reliable. It is clear that further elaboration of 
glucose metabolic brain patterns largely depend on the correct selection of the needed reference 
patient groups for the identifi cation procedure. Expanding sample size will increase sensitivity and 
specifi city of the listed metabolic brain patterns and will enable subclassifi cations in for example 
left/right body-side aff ected patients. Furthermore, a large control sample consisting of suffi  cient 
patients within diff erent age categories is important to study diff erences in brain patterns in an 
aging population and for example in man and women or right and left handedness.
9.4 PARKINSON’S DISEASE-RELATED METABOLIC BRAIN PATTERNS COMPARED TO OTHER 
IMAGE MODALITIES. 
It is increasingly recognized that combining information derived from diff erent image modalities 
can be used for improvements in the sensitivity and specifi city of disease-related patterns for 
parkinsonian disorders. A prospective study was carried out in 20 PD patients and 17 healthy 
controls to test whether FDG-PET scanned on high resolution camera combined with magnetic 
resonance imaging (MRI)-based techniques such as arterial spin labeling (ASL), resting state fMRI 
images and diff usion tensor imaging (DTI) will provide an even more distinguished disease-related 
pattern for Parkinson’s disease. Under normal conditions, the spatial distribution of resting cerebral 
blood fl ow and cerebral metabolic rate of glucose are closely related. 
A relatively new magnetic resonance (MR) technique, pseudo-continuous arterial spin labeling 
(PCASL), (see box 1) was used to measure regional brain perfusion. 
In chapter 8 fourteen Parkinson’s disease patients and seventeen healthy controls could be 
included and underwent FDG-PET imaging and PCASL-MRI. Data were analyzed using scaled 
subprofi le model/principal component analysis (SSM/PCA). We identifi ed a PD-related metabolic 
and perfusion covariance pattern in the same patients using PCASL and FDG-PET imaging and 
assessed (dis)similarities in the disease-related pattern between perfusion and metabolism in PD 
patients. The PD-related metabolic covariance brain pattern is in high accordance with previously 
described disease-related metabolic brain patterns in diff erent cohorts in PD patients. Furthermore, 




perfusion covariance pattern was characterized by relatively decreased cortical metabolic activity 
bilaterally in the temporal, insular, posterior parietal, inferior parietal, lateral occipital and prefrontal 
association cortex. Relative increases were seen in the cerebellum and pons, right thalamus and 
pallidum, sensorimotor cortex, paracentral lobule and supplementary motor area (SMA). Performing 
PCASL and FDG-PET imaging in the same patients enabled a comparison between both patterns. 
The earlier described decreased perfusion in the insular cortex was not present in the  glucose 
metabolic brain pattern, which is suggesting that PCASL is indeed adding relevant information 
to the PD-related pattern. Our perfusion brain pattern is comparable to the earlier described PD-
related perfusion brain pattern (Melzer et al. 2011). The most characteristic diff erence between our 
perfusion brain pattern and previous reports (Fernández-Seara et al. 2012, Melzer et al. 2011) is 
the decrease of cerebral perfusion in the insular cortex on both sides in our data. In support of 
our fi ndings, Helmich used resting-state functional MRI data to test the eff ect of striatal dopamine 
depletion on cortico-striatal network properties. (see box 2 for an explanation of resting state fMRI). 
They showed that PD patients had decreased connectivity between the posterior putamen, which 
is early aff ected in PD (see chapter 2) and various cortical regions contributing to the corticostriatal 
loop, including the insula (Helmich, et al. 2010). Preliminary fi ndings of our own PD patient cohort 
showed that it is possible to adapt the SSM/PCA method to be used for resting state fMRI studies. 
Meaningful patterns of positive and negative correlations were identifi ed when the left pallidum 
Box 1: pseudo-continuous arterial spin labeling
Pseudo-continuous Arterial Spin Labeling (PCASL) permits the noninvasive measurement of 
perfusion with MRI by using a train of radio frequency (RF) pulses and magnetic fi eld gradient 
pulses to achieve labeling of spins in fl owing blood (Dai et al. 2008, van Osch et al. 2009). The 
arterial blood in the feeding artery is magnetically and non-invasively labeled (tagged) and an 
image is acquired after a time delay (i.e. labeled image). The labeled protons in blood act as 
endogenous tracers. They are exchanged with the water protons in brain tissue as the blood 
fl ows into the capillary. At a steady-state of this exchange, the concentration of the labeled 
protons in brain tissue refl ects the amount of blood perfusion which is weighted by regional 
T1 relaxation. A second image (i.e. control image) can be acquired in the same manner except 
that the incoming blood is not magnetically labeled and all the spins in the brain are aligned 
with static magnetic fi eld. The subtraction of label from control image provides an image that 
is proportional to the cerebral blood fl ow, also called the perfusion image (see fi gure below).
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was used as a seed region. Interestingly, a positive correlation was found between the left pallidum 
and the insular cortex on both sides. Future investigations are needed to further optimize the 
technique and use diff erent seed regions to determine resting state connectivity between this 
region and the rest of the brain. 
Another way of  looking at abnormal connectivity patterns between brain regions is diff usion 
tensor imaging (DTI)-tractography. It can be used to visualize nerve fi ber tracts or compute various 
anisotropy measures (see box 3). In our research group we are currently working on optimizing 
protocols for our own PD patient cohort, to be able to answer questions related to changed thalamo-
cortico-striatal connections in PD patients compared to controls. Earlier studies did investigate 
diff usion coeffi  cients and found promising results.
Box 2: Resting state fMRI
In functional magnetic resonance imaging (fMRI), changes in the Blood Level 
Oxygenation Dependent (BOLD) eff ect are measured and visualized in brain tissue. 
fMRI using task-based or stimulus-driven paradigms has been critical to our current 
understanding of brain function. Using the relative signal changes (0.5-5%) from baseline 
in the BOLD signal during the performance of a task or in response to a stimulus, one 
infers that certain areas of the brain are activated or deactivated. In recent years, there has 
been increasing interest in the application of the technique at rest, termed resting-state 
fMRI or functional connectivity MR imaging. In resting state fMRI, subjects are scanned 
without external stimulus to derive brain connectivity patterns which are assumed to 
represent a default-mode network. A seed-based approach is commonly used to identify 
brain regions that are functionally connected (Lee et al. 2012).
Box 3: Diffusion Tensor Imaging
Diff usion magnetic resonance imaging is increasingly used to investigate white matter 
structures in patients with neurodegenerative brain diseases. In Diff usion Weighted 
Imaging the direction of diff usion in each voxel can be determined. This will be used 
to estimate both the presence and orientation of white matter tracts. Diff usion tensor 
imaging (DTI) calculates a tensor in each voxel, taking into account parameters of the 
rate of diff usion and the preferred direction of diff usion. In an isotropic medium (liquor), 
water molecules naturally move randomly and isotropically. In biological tissues however, 
the diff usion may be anisotropic. Fractional anisotropy (FA) can be calculated for each 
voxel and contains combined information in multiple directions. Highly organized white 
matter tracts have high FA because diff usion is highly constrained by the tract’s cellular 
organization. As white matter is damaged, FA decreases due to decreased anisotropic 
diff usion. Apparent diff usion coeffi  cient (ADC) values measure the average water 
diff usion, and increasing ADC values indicate damaged white matter. In addition, DTI-
tractography can be used to visualize nerve fi ber tracts and study abnormal connectivity 
patterns between brain regions. Depending on the goal one can use either a voxel-based 
or skeleton-based approach. In voxel-based approaches one cannot be certain that the 
same regions of white matter tracts correspond across subjects. The tract-based spatial 




Ito compared ADC and FA values in the pons, cerebellum and putamen in patients with PD, MSA and 
controls and detected early pathological involvement prior to magnetic resonance signal changes 
in MSA. In particular, low FA values in the pons showed high specifi city in discriminating MSA from 
PD (Ito et al. 2007).
Although DTI has typically been used to study white matter tracts, it also holds promise to study 
grey matter areas. Vaillancourt demonstrated that the FA values were reduced in the SN of early 
stage, unmedicated patients with PD. The diff erence between de novo patients with PD and healthy 
control subjects was greatest in the caudal ROI of the SN compared with the middle and rostral 
SN ROI. By using this technique, all de novo patients with PD were distinguished from all healthy 
individuals with 100% sensitivity and specifi city (Vaillancourt et al. 2009).
9.5 FUTURE DIRECTIONS
We know now that disease-related metabolic and perfusion brain patterns can be derived in 
patients with neurodegenerative brain diseases. As already suggested in chapter 8, it is increasingly 
recognized that combining information derived from diff erent image modalities including FDG-
PET and PCASL can be used for improvements in the sensitivity and specifi city of biomarkers for 
parkinsonian disorders. However, complexity regarding analysis techniques increases. 
9.6 DECISION TREE CLASSIFICATION OF FDG-PET DATA TO PREDICT NEURODEGENERATIVE 
BRAIN DISEASES
As described above, diff erent image modalities can be used to extract disease-related metabolic 
brain patterns in neurodegenerative brain diseases. However, the above described SSM/PCA 
method can only deal with one image modality, and comparison of two classes (healthy and patient 
group, or two patient groups) at a time. This puts forward a research challenge to improve the SSM/
PCA method. Regarding previous suggestions to select components used for creating a disease-
related metabolic pattern (Spetsieris and Eidelberg. 2010), one might consider machine learning 
approaches like decision-tree methods to improve sensitivity and specifi city (Quinlan. 1993). (see 
box 4 for an explanation and example of the decision tree method). The objective for future research 
will be to explore the fi rst examples of the decision tree method by carefully looking at each step in 
the tree, identify misclassifi ed patients and get validated results. Furthermore, besides being able to 
classify patients of diff erent patient groups in one analysis, it is possible to use characteristic image 
features derived from multimodal brain data (FDG-PET, DTI, PCASL and resting state fMRI images). 
From these data, image features and network patterns can be extracted, which can be used as input 
for the decision tree method. Another advantage of this method is that non-linear combinations 
of image features can be used. This will result in a supervised classifi cation method for associating 




FDG-PET imaging is increasingly available for routine clinical practice and has remained the only 
available radiotracer to detect accurately and reliably the cerebral glucose metabolism. The SSM/
PCA method can identify relationships in relatively increased and decreased metabolic activity 
between diff erent brain regions in combined samples of patients and controls. The expression of a 
covariance pattern can be quantifi ed in an individual patient. The obtained subject score indicates to 
Box 4: Decision tree
Decision tree method is an approach for analytically making decisions and uses graphical 
representation of decision tree(s) to present several decision classes. Decision trees have 
been known for their capability in classifi cation of objects and  they can be modifi ed as new 
cases or more information from diff erent image modalities is presented. 
In this example carried out by the Visualization and Computer Graphics group (RUG), 
a decision tree program (c4.5 by Quinlan (Quinlan. 1993)) was adapted to be used as a 
machine learning technique to classify neurodegenerative brain diseases. The decision 
tree program has been used to classify subjects as healthy, PD, MSA or PSP together in 
one analysis with respect to their individual subject score calculated for each principal 
component of each patient group instead of one score for the disease-related combination 
pattern. The data consists of 76 subjects (18 healthy controls, 20 PD, 21 MSA and 17 PSP) 
(see chapter 5) and in total 112 principal components (38 PD, 39 MSA and 35 PSP). The 
decision tree shows in oval shapes the features (principal components used in the process 
of classifi cation), the conditions on which decisions are made, and the resulting classes 
(decisions) are presented in rectangles. Below an example of an output of the decision tree 
method is shown.
Interestingly, the fi rst 15 of the MSA patients are classifi ed by using a component which 
belongs to PSP. When looking at the metabolic pattern of PSP PC11, it consists mainly of 
increased metabolic activity in the putamen. MSA patients have decreased metabolism 
in the putamen and this is probably the reason why patients with a low subject score for 
this component can be classifi ed. Another key component in this example is PD PC 7. The 
pattern in this component consists of decreased metabolism in thalamus, caudate nucleus, 
mesencephalon and prefrontal areas. These regions are typically decreased in PSP patients 




what extent that patient expresses the disease-related pattern. These metabolic brain patterns can 
therefore be a valuable aid in the diff erential diagnosis of individual patients with neurodegenerative 
brain diseases. Furthermore, we propose that a disease biomarker can be identifi ed by using 
decision tree methods to combine network patterns from diff erent image modalities derived from 
patients with parkinsonian and dementia syndromes. This disease biomarker is expected to help in 
diagnosing patients at an early stage of the disease and can be used to track disease progression 







The main aim of this thesis was to investigate diff erences in glucose metabolism in various 
neurodegenerative brain diseases using [18F]-fl uorodeoxyglucose (FDG)-PET imaging. Furthermore, 
specifi c analysis techniques which can assist in the applicability of these brain patterns in clinical 
practice were investigated. In the following paragraphs specifi c fi ndings will be summarized and 
discussed. 
The diff erential diagnosis of neurodegenerative brain diseases may be diffi  cult on clinical 
grounds only. Parkinson’s disease (PD) is the second most common neurodegenerative brain disease 
after Alzheimer’s disease (AD). It can be diffi  cult to distinguish PD from other neurodegenerative 
parkinsonian syndromes such as multiple system atrophy (MSA), progressive supranuclear 
palsy (PSP), corticobasal degeneration (CBD) or dementia with Lewy Bodies (DLB). In chapter 2, 
radiotracer neuroimaging techniques using positron emission tomography (PET) or single photon 
emission computed tomography (SPECT) are discussed which can be helpful to diff erentiate PD 
from other diseases. In order to diff erentiate between neurodegenerative brain diseases, disease-
related metabolic brain patterns identifi ed with FDG-PET imaging could be of great assistance in the 
individual clinical diagnosis.
FDG-PET imaging is increasingly available for routine clinical practice and has remained the 
only available radiotracer to detect the cerebral glucose metabolism accurately and reliably. As 
glucose is the only source of energy for the brain, it refl ects the energy needs of underlying brain 
neuronal systems. After being taken up by the brain, glucose or its radiotracer analogue [18F]FDG, 
are phosphorylated by hexokinase to glucose-6-PO4 or fl uorodeoxyglucose-6-PO4, the fi rst step of 
the glycolytic process. However, FDG being a deoxy variant of glucose, is not a substrate for further 
metabolism and is consequently trapped in brain tissue for the duration of the scanning procedure. 
The outcome measure of regional cerebral FDG-uptake measured by PET, therefore, is the fi rst step 
of the glycolysis. The detected disease-related metabolic brain patterns using FDG-PET refl ect the 
underlying pathological alterations of the aff ected brain regions. 
In chapter 3 we have performed a retrospective study selecting typical patients with PD, MSA, PSP, 
CBD DLB, AD and frontotemporal dementia (FTD). At the time of referral for imaging, the clinical 
diagnosis of most patients was uncertain. 
To identify diff erences between patients and healthy controls we used a univariate voxel-based 
analysis technique called statistical parametric mapping (SPM). Images of each of the 7 patient 
groups were separately compared to 18 healthy controls using this SPM procedure and a two-
sample t-test. Disease-specifi c patterns of relatively decreased metabolic activity were found in 
PD (contralateral parieto-occipital and frontal regions), MSA (bilateral putamen and cerebellar 
hemispheres), PSP (prefrontal cortex and nucleus caudatus, thalamus and mesencephalon), 
CBD (contralateral cortical regions), DLB (occipital and parieto-temporal regions), AD (parieto-
temporal regions), and FTD (fronto-temporal  regions). In these patients, scanned at an early 
disease stage, typical diff erences between patient groups healthy control were found for each 
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disease. In chapter 4 an overview of the literature of disease-specifi c metabolic brain patterns in 
several neurodegenerative brain diseases is given. Furthermore, advances of using multivariate 
analysis methods compared to univariate methods are outlined. In a multivariate statistical analysis 
technique, called Scaled Subprofi le Modelling/Principal Component Analysis (SSM/PCA), not only 
group diff erences between patients and controls can be identifi ed like in univariate methods, but 
it is also possible to identify relationships in relatively increased and decreased metabolic activity 
between diff erent brain regions in combined samples of patients and control scans.
Multivariate analysis method
In chapter 5 we validated disease-related metabolic brain patterns for PD, MSA and PSP using 
SSM/PCA in the same patients and controls that were used in the univariate analysis of chapter 3. 
Results showed that the disease-related metabolic brain patterns were highly similar to  the earlier 
described group diff erences and discriminative of the three disorders. 
In chapter 6 we identifi ed an Alzheimer’s Disease-related glucose metabolic brain pattern using 
the SSM-PCA methods. Group diff erences in regional cerebral glucose utilisation of patients with 
dementia compared to healthy controls are well-known. However, multivariate analysis techniques 
aiming at identifying diagnostic neural networks in diseases, have been applied less frequently. 
The aim of this study was to present and validate an AD-related glucose metabolic brain pattern 
and to apply it prospectively in a second cohort of individual patients with memory complaints. 
The identifi cation cohort consists of the same AD patients and controls as described in chapter 
3. The AD-related glucose metabolic brain pattern was characterized by relatively decreased 
metabolic activity in the temporal and parietal regions and relatively increased metabolic activity 
in the subcortical white matter, cerebellum and sensorimotor cortex with a sensitivity of 93% and a 
specifi city of 94%. Furthermore, we applied this method to investigate the ability of the identifi ed 
AD-related metabolic covariance pattern to discriminate between individual patients with probable 
AD and non-probable AD (possible AD, mild cognitive impairment (MCI) or subjective complaints) 
and the association of the metabolic patterns with neuropsychological tests. In the confi rmation 
cohort, all the subjects with clinically probable AD diagnosis showed a high expression of the AD-
related metabolic brain pattern whereas in all the subjects with a non-probable AD diagnosis a low 
expression was found. 
In chapter 7 we present the prospective Dutch multicenter imaging project GLucose IMaging in 
ParkinsonismS (GLIMPS) which aims at testing the feasibility of a novel image-based classifi cation 
algorithm for the accurate and early individual diagnosis of patients with neurodegenerative brain 
diseases. It is increasingly recognized that combining information derived from diff erent image 
modalities can be used for improvements in the sensitivity and specifi city of disease-related 
patterns for parkinsonian disorders. 
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Extending to other image modalities
A prospective study was carried out in 20 PD patients and 17 healthy controls to test whether FDG-
PET scanned on a high resolution camera combined with magnetic resonance imaging (MRI)-based 
techniques such as arterial spin labeling (ASL), resting state fMRI images and diff usion tensor imaging 
(DTI) will provide an even more distinguished disease-related pattern for Parkinson’s disease. 
Besides studying glucose metabolism, it is possible to study brain perfusion with a relatively new 
magnetic resonance based technique called pseudocontinous arterial spin labeling (PCASL). In 
chapter 8 we identifi ed a PD-related metabolic and perfusion covariance pattern in the same 
patients using PCASL and FDG-PET imaging and assessed (dis)similarities in the disease-related 
pattern between perfusion and metabolism in PD patients. 
The PD-related metabolic covariance brain pattern is in high accordance with disease-related 
metabolic brain patterns in diff erent cohorts in PD patients previously described, showing 
bilaterally decreased metabolic activity in the (posterior) parietal association cortex, inferior parietal 
cortex, lateral occipital cortex, prefrontal association cortex and SMA. Relative increases were seen 
in the cerebellum and pons, thalamus and pallidum, sensorimotor cortex, limbic association cortex, 
paracentral lobule and left SMA. (see also chapter 5). 
Furthermore, we obtained a disease-specifi c perfusion brain pattern using PCASL-MR imaging. 
Our perfusion brain pattern is comparable to  the previously described PD-related perfusion brain 
patterns. We know now that disease-related metabolic and perfusion brain patterns can be derived 
in patients with neurodegenerative brain diseases. As suggested in chapter 8, it is increasingly 
recognized that combining information derived from diff erent image modalities including FDG-
PET and PCASL can be used for improvements in the sensitivity and specifi city of biomarkers for 
parkinsonian disorders. However, complexity regarding analysis techniques increases. 
As described above diff erent image modalities can be used to extract disease-related metabolic 
brain patterns in neurodegenerative brain diseases. However, the above described SSM/PCA 
method can only deal with one image modality, and comparison of two classes (healthy and patient 
group, or two patient groups) at a time. This puts forward a research challenge to improve the SSM/
PCA method. One might consider machine learning approaches like decision-tree methods to 
improve sensitivity and specifi city. 
CONCLUSION 
FDG-PET imaging is increasingly available for routine clinical practice and has remained the only 
available radiotracer to detect the cerebral glucose metabolism accurately and reliably. The SSM/
PCA method can identify relationships in relatively increased and decreased metabolic activity 
between diff erent brain regions in patients and controls. The expression of a covariance pattern 
can be quantifi ed in an individual patient. The obtained subject score indicated to what extent 
that individual patient expresses the disease-related pattern. These metabolic brain patterns can 
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Neurodegeneratieve hersenziekten zijn hersenaandoeningen waarbij langzamerhand – over vele 
jaren -  de zenuwcellen in bepaalde gebieden verloren gaan. Vaak  is de oorzaak van deze hersenziekten 
onbekend en zijn de behandelingsmogelijkheden beperkt. De laatste tientallen jaren wordt echter 
veel onderzoek naar deze aandoeningen gedaan met de verwachting dat dit zal resulteren in beter 
inzicht en betere behandelingsmogelijkheden. Voorbeelden van neurodegeneratieve ziekten zijn 
onder andere Ziekte van Parkinson (PD), multisysteem atrofi e (MSA), progressieve supranucleaire 
parese (PSP), Corticobasale degeneratie (CBD) en Dementie met Lewy Bodies (DLB). Deze 
ziekten hebben gemeenschappelijk dat ze allemaal in meer of mindere mate parkinsonistische 
verschijnselen hebben (stijfheid, traagheid, rusttremor, balansproblemen). Daarnaast kunnen bij 
sommige aandoeningen op een bepaald moment in de ziekte geheugenklachten, problemen met 
het uitvoeren van complexe taken en visuele hallucinaties optreden. Bij de ziekte van Alzheimer 
(AD) staan vooral geheugenproblemen op de voorgrond en bij frontotemporale dementie (FTD) 
kunnen gedragsverandering en problemen met taal voorkomen. Alle bovenstaande  aandoeningen 
vallen onder de categorie neurodegeneratieve hersenziekten. 
Een precieze diagnose stellen kan vooral in een vroeg ziektestadium lastig zijn omdat de symptomen 
van patiënten op elkaar lijken. Het beloop van de ziekte in de tijd (welke symptomen precies, 
snelheid, ernst) leiden uiteindelijk naar de juiste diagnose. Hier kan soms jaren overheen gaan. Het 
is echter wel van belang voor de patiënt voor de prognose, en soms ook voor de behandeling om in 
een vroeg ziektestadium een precieze diagnose te kunnen stellen. 
Een aantal nieuwe beeldvormende technieken kunnen medisch specialisten, zoals de neuroloog, 
helpen om in een beginstadium van een ziekte een beter onderscheid tussen de verschillende 
neurodegeneratieve hersenziekten te maken. In hoofdstuk 2 worden verschillende radiotracer 
neuroimagingtechnieken besproken die kunnen helpen bij het onderscheid tussen PD en overige 
neurodegeneratieve hersenziekten. 
Om een onderscheid binnen de groep neurodegeneratieve hersenziekten te maken kan een [18F]-
fl uorodeoxyglucose (FDG)-PET scan behulpzaam zijn. Bij dit onderzoek wordt de radiotracer FDG 
(dit is een vorm van glucose (suiker)) ingezet. Glucose is normaal gesproken de enige energiebron 
van hersenweefsel. Door een FDG-PET scan van de hersenen te maken wordt zichtbaar welke 
hersengebieden meer of minder energie gebruiken en dus goed of minder goed functioneren 
volgens een bepaald patroon. Deze patronen van verminderde en soms verhoogd energieverbruik 
oftewel het glucosemetabolisme zijn verschillend voor de genoemde neurodegeneratieve 
hersenziekten en kunnen ook al aanwezig zijn in het begin van deze hersenziekten.
Het doel van dit proefschrift was om met behulp van een FDG-PET scan het glucose metabolisme 
in de hersenen bij neurodegeneratieve hersenziekten in beeld te brengen. Daarnaast werden 
verschillende analysetechnieken en ook andere beeldvormende MRI technieken onderzocht om de 
ziekte-specifi eke metabole patronen weer te geven. 
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In hoofdstuk 3 hebben wij retrospectief FDG-PET scans geanalyseerd van patiënten in een vroeg 
ziektestadium met verschillende neurodegeneratieve hersenziekten.
In totaal werden 96 patiënten geïncludeerd die een klinische FDG-PET scan ondergingen en voldeden 
aan klinische onderzoekscriteria waarvan 20 met de ziekte van Parkinson (PD), 21 multisysteem 
atrofi e (MSA), 17 progressieve supranucleaire parese (PSP), 10 corticobasale degeneratie (CBD), 6 
dementie met lewy bodies (DLB), 15 ziekte van Alzheimer (AD) en 7 frontotemporale dementie (FTD). 
De FDG-PET beelden werden geanalyseerd en vergeleken met 18 gezonden via Statistical Parametric 
Mapping (SPM5).  Verlaagde metabole activiteit in bepaalde hersengebieden ten opzichte van 
gezonde controles werd gevonden in PD (contralateraal parieto-occipitaal, frontaal), MSA (bilateraal 
putamen, cerebellum), PSP (prefrontale cortex, nucleus caudatus, thalamus, mesencephalon), CBD 
(contralaterale corticale regio’s), DLB (occipitaal, parieto-temporaal), AD (parieto-temporaal) en FTD 
(fronto-temporaal). In deze patiënten die gescand waren in een vroeg ziektestadium waren dus 
typische verschillen tussen patiënten groepen en gezonden te zien.
In hoofdstuk 4 wordt een literatuur overzicht gegeven van ziekte-specifi eke metabole patronen bij 
verschillende neurodegeneratieve hersenziekten. Daarnaast wordt in dit hoofdstuk een bepaalde 
wiskundige techniek uitgelegd, de zogenoemde scaled subprofi le model/principal component 
analyse (SSM-PCA). Dit is een multivariaat methode gebaseerd op principal component analyse 
waarmee het verschil in hersenpatronen in een gecombineerde groep gezonden en patiënten 
gevonden kan worden en weergegeven in een ziekte–specifi ek metabool patroon. Het laat relaties 
zien welke men niet zo direct op het oog kan zien en het bepaalt de kans dat veranderingen in het 
glucosemetabolisme in verschillende hersengebieden bij elkaar horen in een patroon.
Het grote voordeel van deze analyse methode is dat niet alleen twee groepen onderling 
vergeleken kunnen worden, maar dat ook de bijdrage van elk individu ten opzichte van het patroon 
berekend kan worden. Dit betekent dat voor elke nieuwe patiënt met behulp van deze methode 
een score (de zogenaamde z-score) berekend kan worden die weergeeft hoeveel het metabole 
hersenpatroon van die patiënt lijkt op het ziekte-specifi eke metabole groepspatroon van die ziekte. 
Hoe hoger de z-score, (hoge expressie van het ziekte-specifi eke patroon bij dat individu), hoe groter 
de kans (hogere waarschijnlijkheid) dat die patiënt ook die bepaalde ziekte heeft. Deze scores 
kunnen berekend worden voor elk beschikbaar en gevalideerd ziekte-specifi ek metabool patroon.
In hoofdstuk 5 valideerden wij het ziekte-specifi eke metabole patroon voor PD, MSA en PSP 
met behulp van deze SSM/PCA analyse waarbij bleek dat met behulp van deze patronen een 
goed onderscheid tussen de verschillende ziektebeelden gemaakt kon worden. In hoofdstuk 6 
identifi ceerden wij het Alzheimer-gerelateerde metabole patroon en pasten het daarnaast toe in 
een prospectieve groep patiënten onderverdeeld in een waarschijnlijk en niet- waarschijnlijk ziekte 
van Alzheimergroep. Voor elke patiënt werd een z-score berekend voor het AD-gerelateerde patroon 
die weergeeft hoeveel die patiënt lijkt op het ziekte-specifi eke AD groepspatroon. Het bleek dat de 
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patiënten uit de “waarschijnlijke”AD-groep inderdaad een hoge score hadden voor het AD-patroon 
en patiënten met “niet-waarschijnlijke” AD een lage score hadden.
In hoofdstuk 7 presenteren wij het GLIMPS project (GLIMPS is een acroniem voor GLucose IMaging 
in ParkinsonismS). Dit is een landelijk project, gecoördineerd vanuit het UMC Groningen, waaraan 
verschillende ziekenhuizen in Nederland meedoen. Het doel van dit project is om de diagnostiek 
bij patiënten in een vroege fase van een neurodegeneratieve hersenziekte te verbeteren door 
systematisch de het glucose metabolisme in de hersenen bij patiënten met neurodegeneratieve 
hersenziekten te onderzoeken met behulp van een FDG-PET scan.
Bij het beoordelen van een patroon bij een individuele patiënt is het van belang een krachtige 
referentiegroep van bekende ziekte-specifi eke metabole patronen van bepaalde patiëntengroepen 
ter vergelijking te hebben. Het landelijk verzamelen van deze metabolepatronen bij patiënten 
slechts sinds kort mogelijk aangezien thans FDG-PET in de meeste grote regionale centra in 
Nederland beschikbaar is. 
Daarnaast wordt het steeds duidelijker dat een combinatie van verschillende beeldvormende 
technieken zoals verschillende MRI scans kunnen bijdragen aan een verbeterde omschrijving van 
ziekte-specifi eke metabole patronen van de hersenen. Een prospectieve studie werd uitgevoerd 
bij 20 Parkinsonpatiënten en 17 gezonde vrijwilligers om te onderzoeken of FDG-PET gescand met 
een hoge resolutie camera gecombineerd met verschillende MRI scans zoals Arterial Spin Labeling 
(ASL), resting state fMRI en diff usion tensor imaging (DTI) een nog beter en duidelijker ziekte-
specifi ek patroon voor de ziekte van Parkinson zou opleveren. 
In hoofdstuk 8 werd het ziekte-specifi eke Parkinsonpatroon gemeten met de hoge resolutie FDG-
PET scan vergeleken met het patroon gevonden met ASL, een techniek om de doorbloeding (perfusie) 
in de hersenen te meten. Het metabole patroon voor PD gemeten met FDG-PET komt overeen met 
het eerder beschreven PD-patroon in hoofdstuk 5 en eerdere literatuur. Daarnaast is het mogelijk 
gebleken om een ziekte-specifi ek metabool- en perfusie-patroon bij dezelfde Parkinsonpatiënten 
te vinden. Beide patroon lijken veel op elkaar, maar er zijn ook enkele verschillen. We concludeerden 
dat het combineren van verschillende soorten scans, PET en MRI, meer inzicht kan geven in de 
onderliggende pathologische processen, maar dat de complexiteit van de data-analyse toeneemt. 
Ook worden de analysemethoden zelf verder ontwikkeld om voor de toekomst de technieken nog 
gevoeliger te maken voor de verschillen tussen de neurodegeneratieve hersenziekten. 
CONCLUSIE
FDG-PET is steeds meer beschikbaar voor de klinische praktijk en is nog steeds de meest betrouwbare 
techniek die nauwkeurig het energieverbruik in de hersenen laat zien. De wiskunde rekentechniek 
SSM/PCA kan verbanden tussen verhoogde en verlaagde glucose metabolisme in verschillende 
hersenengebieden in 1 patroon voor elke neurodegeneratieve apart laten zien. Vervolgens kan met 
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behulp van een rekenmethode een score berekend worden die weergeeft hoeveel het metabole 
hersenpatroon van een individuele patiënt lijkt op het ziekte-specifi eke metabole groepspatroon 
van bv PD, MSA of PSP. Hoe hoger deze score, hoe meer het hersenpatroon van de individuele 
patiënt lijkt op het groepspatroon en des te waarschijnlijker het is dat de patiënt deze ziekte heeft. 
Daarom kunnen bij patiënten met neurodegeneratieve hersenziekten deze ziekte-specifi eke 
metabole patronen in de hersenen een waardevol hulpmiddel zijn in de klinische praktijk bij het 
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